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SUMMARY
Introduction
Contemporary techniques in radiotherapy (RT), which include intensity modulated ra-
diation therapy (IMRT), volumetric modulated arc therapy (VMAT), and proton and heavy ion 
therapy, enable the delivery of high dose coverage of tumor volume while sparing healthy sur-
rounding tissue. At the same time, imaging techniques such as positron emission tomography/
computed tomography (PET/CT) and magnetic resonance imaging (MRI) have evolved to al-
low for the visualization of a wide range of pathophysiological characteristics of tumor, from 
metabolism to perfusion. Diffusion-weighted (DW)-MRI provides an estimate of the diffusivity 
of water molecules in tissue, with the quantitative imaging metric apparent diffusion coeffi-
cient (ADC) providing valuable information about changes in tissue cellularity associated with 
tumors in addition to predictions of treatment outcomes after RT. Dynamic contrast enhanced 
(DCE-) MRI provides information on tumor perfusion using contrast agents (CA) to assess the 
vascular properties of tissue through a gadolinium (Gd)-based CA, also associated with therapy 
response. On the other hand, PET/CT imaging relies on specific radiotracers, with  18-fluorine 
fluorodeoxyglucose (18F-FDG) being the most widely used in cancer. This radiotracer can be 
used to measure metabolic and functional properties of tumors.
The combination of functional and molecular information that can be derived from MRI 
and PET/CT imaging techniques has led to the development of new tools that go beyond uni-
form dose delivery. Clinical practice in the coming years is expected to progress further down 
the path of RT treatment adapted to an individualized response - turning from prescribing dose 
to volume towards prescribing dose to optimizing treatment, minimizing the number of tumoral 
cells that survive treatment with acceptable comorbidity. This thesis will focus on the building 
blocks of adaptive RT for Human Papilloma Virus negative (HPV-) Head and Neck Squamous 
Cell Carcinoma (HNSCC) and Brain Metastases (BM) patients.
– XVI –
Motivation and objectives
In the modern era of adaptive RT, it has become vital to understand how different func-
tional imaging techniques interact and link together in tumors. There is an urgent need to as-
sess tumor response during treatment using functional imaging. Hence, in clinical settings it is 
extremely essential to accurately assess whether or not a tumor has been successfully treated 
and whether the tumor requires additional treatment. Quantitative Imaging Biomarkers (QIBs) 
may play a crucial role in deciphering treatment efficacy. However, the implementation of these 
functional techniques is one of the most challenging issues in RT.
The objectives of this dissertation are divided into the three parts below, each corre-
sponding to its respective study.
Part I -  DW-MRI and 18F FDG PET/CT are two valuable imaging techniques that 
may help build the framework for adaptive radiotherapy based on func-
tional images in the future by investigating tumor cellularity and glucose 
metabolism before, during and after RT in HPV- HNSCC.
Part II -  A constant challenge in functional imaging is the improvement of im-
age quality and the reduction of distortion to obtain quality images for 
radiation treatment planning and delivery. This study investigates the ap-
plication of the reversed gradient method in DW-MRI for the reduction of 
geometric distortion and measurement of accurate ADC.
Part III – a.  For QIBs to be used in Adaptive RT, it is a prerequisite to perform ex-
haustive phantom studies detailing the repeatability and reproducibility of 
the functional imaging technique.
Part III – b.  Intra Voxel Incoherent Motion (IVIM) DW- and DCE- MRI are two prom-
ising imaging techniques that may help evaluate early treatment response 
in BM patients treated with SRS. 
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Results
Results from the studies related to the objectives above are divided into three corre-
sponding parts. The studies in Part I and Part II were performed at Meixoeiro University 
Hospital of Vigo, Spain. The study in Part III a. and Part III b. was conducted at Memorial 
Sloan-Kettering Cancer Center, USA.
Part I -  The study showed an increase in the relative percent change in ADC at 
week 2 for the patient with no evidence of disease (NED) reflecting a 
good response to treatment in both primary tumor and neck nodal metas-
tases. ADC histograms showed microstructural heterogeneity in primary 
tumor and neck nodal metastases in the three groups NED, dead of disease 
(DOD) and alive with disease (AWD). In addition, in the NED patient, a 
shift towards high ADC values for both primary tumor and neck nodal 
metastases reflected the improved pathologic response to RT. The ADC 
relative percent change trends shown for primary tumor and neck nodal 
metastases depict the different responses to treatment, suggesting the pos-
sibility of identifying at an early stage patients with good or bad progno-
ses to individualize and adapt RT treatment. 
Part II -  In this study, a new phantom was specifically designed to evaluate geometri-
cal distortion. The visual improvement in registration with the reversed gradi-
ent method applied was notable, showing a better fit with the real anatomic 
position indicated by CT. The numerical quantification of distortion calculat-
ed through the mutual information metric in undistorted DW-MRI images for 
both phantom and patients with different b-values showed an improvement in 
the mutual information metric with respect to distorted images. 
Part III – a.  This study assessed the repeatability, reproducibility and quantitative 
quality control of ADC measurements across vendors of the same field 
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strength using a standardized acquisition protocol and a temperature-con-
trolled fluid phantom. ADC values acquired for the phantom from differ-
ent vendors showed no statistical difference between the four measure-
ments performed within and across vendors and between different ROIs. 
In addition, coefficient of variation of the repeatability measurements for 
each vendor was < 2%. 
Part III – b.  The present study showed a significantly strong positive correlation between 
mean ADC and mean true diffusion coefficent (D), mean perfusion factor (f) and 
mean plasma volume fraction (vp) and volume transfer constant (Ktrans), mean 
Ktrans and mean extracellular volume fraction (ve). ADC, D and Ktrans histograms 
display microstructural and microvasculature heterogeneity in tumor tissue. The 
distribution curves of early post-treatment ADC and Ktrans show a shift towards 
higher ADC and lower Ktrans values, reflecting the improved pathologic response 
to SRS. In terms of response to treatment, in a long term follow up of 12 months, 
ADC values and tumor volumes showed the same behavior.
Conclusions
The conclusions drawn from these results have also been divided into three correspond-
ing parts.
Part I -  Multimodality imaging in HPV- HNSCC suggests that tumor cell density 
is inversely proportional to glucose metabolism. The survival status and 
functional metrics show different trends.
Part II -  A clear improvement in mutual information for registration processes were 
observed when the reversed gradient method was applied. Thus, this method 
improves registration and provides accurate ADC measurement in tumors. 
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Part III – a.  The establishment of methodological procedures and the standardization 
of data acquisition conditions are needed for the systematic reproducibil-
ity and repeatability of DW-MRI studies.
Part III – b.  Early changes in diffusion and perfusion imaging metrics to SRS can be 
detected in a manner similar to the changes associated with radiation ef-
fects in other studies. Predicting response at the early stages would be 
advantageous over methods that require long term clinical follow up and 
will help to individualize and adapt RT treatment.
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RESUMEN
Introducción
Hoy en día, novedosas técnicas radioterápicas como la radioterapia de intensidad 
modulada (IMRT),  la arcoterapia volumétrica modulada (VMAT), la protonterapia y la 
hadronterapia permiten administrar una alta dosis de cobertura al volumen tumoral evitan-
do el tejido sano circundante. Al mismo tiempo, técnicas de imagen como la tomografía de 
emisión de positrones-tomografía computarizada (PET/CT) y las imágenes por resonancia 
magnética (MRI) han madurado permitiendo visualizar un amplio rango de característi-
cas pato-fisiológicas del tumor, desde el metabolismo a la perfusión. La técnica Diffusion 
Weighted  (DW-) MRI proporciona una estimación de la difusión de las moléculas de agua 
en tejido a través de la métrica de imagen cuantitativa, coeficiente de difusión aparente 
(ADC). Dicha métrica proporciona valiosa información tanto acerca de la celularidad del 
tumor así como un valioso indicador de la respuesta tumoral al tratamiento con radiotera-
pia. Además, la técnica dynamic contrast enhanced (DCE-) MRI proporciona información 
de la perfusión tumoral utilizando medios de contraste; las métricas derivadas de esta téc-
nica nos permiten evaluar las propiedades vasculares del tejido a través de un medio de 
contraste basado en gadolinio, estas métricas están también asociadas con la respuesta al 
tratamiento. Por otro lado, las imágenes de PET/CT dependen  de radiotrazadores específi-
cos, siendo 18F-labeled fluorodeoxyglucose (18F-FDG) el más extendido y usado en cáncer. 
Este radiotrazador puede ser usado para medir las propiedades metabólicas y funcionales 
de los tumores.
La combinación de información funcional y molecular que puede ser obtenida de téc-
nicas de imagen como MRI y PET/CT, ha conllevado al desarrollo de nuevas herramientas 
que van mas allá de la administración de una dosis uniforme. Se espera que la práctica clínica 
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en los próximos años evolucione, convirtiendo la dosis prescrita al volumen hacia la prescrip-
ción de dosis para optimizar el tratamiento, minimizando el número de células tumorales que 
sobreviven al tratamiento con comorbilidad aceptable y adaptando el tratamiento radioterá-
pico a una respuesta individualizada. Esta tesis se enfocara en el elemento esencial de la 
radioterapia adaptativa basada en imágenes funcionales para Carcinomas de cabeza y cuello 
de células escamosas (HNSCC) y metástasis cerebrales (BM).
Motivación y Objetivos
En la era moderna de la radioterapia adaptativa, se ha convertido de vital importan-
cia entender como diferentes técnicas de imagen funcional interactúan en su aplicación a 
tumores. Hay una necesidad urgente de evaluar la respuesta tumoral durante el tratamiento 
utilizando imágenes funcionales. Por lo tanto en la práctica clínica es extremadamente es-
encial evaluar con precisión si un tumor ha sido tratado con éxito o si el tumor necesita de 
tratamiento adicional. Los biomarcadores de imagen cuantitativa  deben jugar un papel cru-
cial en descifrar la eficacia del tratamiento. Sin embargo, la implementación de estas técnicas 
funcionales es uno de los aspectos más desafiantes en radioterapia.
Los objetivos de esta tesis están divididos en tres partes correspondiéndose cada una a 
su respectivo estudio. 
Parte I –  DW-MRI y 18F FDG PET/CT son dos valiosas técnicas de imagen que 
pueden ayudar a construir el marco de la futura radioterapia adaptativa 
basada en imágenes funcionales, investigando la celularidad del tumor 
y el metabolismo de la glucosa antes, durante y después del tratamiento 
radioterápico, en cánceres de cabeza y cuello de células escamosas en 
pacientes negativos al virus papiloma humano (HPV-).
Parte II –  Un reto constante en imagen funcional es el de mejorar la calidad de 
imagen y reducir la distorsión para obtener imágenes de calidad para la 
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planificación y tratamiento en radioterapia. Este estudio investiga la apli-
cación del método de los gradientes invertidos in DW-MRI para reducir 
la distorsión geométrica y medir con precisión el ADC.
Parte III – a.  Para usar biomarcadores de imagen cuantitativa en radioterapia adapta-
tiva, es un prerrequisito realizar exhaustivos estudios con maniquís que 
detallen la repetitividad y reproducibilidad de la técnica de imagen fun-
cional.
Parte III – b.  Intravoxel Incoherent Motion DW-MRI y DCE-MRI son dos promet-
edoras técnicas de imagen que pueden ayudar a evaluar la respuesta al 
tratamiento temprana en pacientes con BM tratados con radiocirugía es-
tereotáctica (SRS).
Resultados
Los resultados obtenidos de los objetivos detallados por partes anteriormente están divi-
didos igualmente en tres partes. Los estudios de la Parte I  y la  Parte II se han desarrollado en 
el Hospital Meixoeiro de Vigo, España. El estudio de la Parte III a. y b. se han desarrollado en 
Memorial Sloan-Kettering Cancer Center, USA.
Parte I –  Este estudio muestra un incremento en el cambio relativo en porcen-
taje de ADC en la segunda semana de tratamiento para un paciente sin 
evidencia de enfermedad (NED), en comparación con pacientes muer-
tos por enfermedad (DOD) y vivos pero con enfermedad (AWD), tanto 
en tumor primario como en nódulos metastásicos de cuello, reflejando 
una buena respuesta al tratamiento. Los histogramas de ADC muestran 
heterogeneidad microestructural en el tumor primario y en los nódulos 
metastásicos de cuello, en los tres grupos (NED, DOD y AWD). Además, 
en el paciente NED un desplazamiento hacia valores mas altos de ADC 
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en el tumor primario y en el nódulo metastásico de cuello, reflejan la 
mejora patológica en la respuesta a radioterapia. Las tendencias del cam-
bio relativo en porcentaje de ADC para el tumor primario y el nódulo 
metastásico de cuello describen diferentes respuestas al tratamiento su-
giriendo que la identificación en un estado temprano de pacientes con 
buen o mal pronóstico pude ayudar a la individualización y adaptación 
del tratamiento radioterápico.
Parte II –  En esta segunda parte, un novedoso maniquí fue específicamente dis-
eñado para evaluar la distorsión geométrica. La mejora visual en el 
registro de imágenes aplicando el método de los gradientes invertidos, 
mostró un mejor ajuste a la posición anatómica real en la CT. La cuan-
tificación numérica de la distorsión calculada a través de la métrica de 
información mutua en imágenes corregidas de DW-MRI, tanto para el 
maniquí como para los pacientes mostró una mejora con respecto a las 
imágenes no corregidas.
Parte III – a.  Este estudio evaluó la repetitividad, reproducibilidad y el control de 
calidad cuantitativo en medidas de ADC entre resonancias de distin-
ta marca de la misma intensidad de campo magnético, utilizando un 
protocolo de adquisición estandarizado y un maniquí liquido de tem-
peratura controlada. Los valores adquiridos de ADC para el maniquí 
en diferentes marcas, no mostraron diferencias significativas entre las 
cuatro medidas realizadas en cada una de ellas y entre marcas. Por otro 
lado se ha obtenido un coeficiente de variación menor del 2% en las 
medidas de repetitividad para cada marca.
Parte III – b.  El presente estudio mostró una fuerte correlación positiva y significativa 
entre ADC y D, f y vp, f y K
trans, Ktrans y ve. Los histogramas de ADC, D 
y Ktrans reflejan la heterogeneidad de la microestructura y la microvas-
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culatura del tejido tumoral. Las curvas de distribución en un momento 
temprano postratamiento muestran para ADC  y Ktrans un desplazamiento 
hacia valores elevados de ADC y bajos de Ktrans, reflejando la mejora 
de la respuesta patológica a la SRS. En términos de respuesta al trata-
miento, en un seguimiento a 12 meses de los pacientes postratamiento, 
los valores de ADC y de volumen tumoral muestran un mismo compor-
tamiento.
Conclusiones
Las conclusiones relacionadas con los resultados están divididas en tres partes: 
Parte I –  Las imágenes multimodales en HPV- HNSCC sugieren que la den-
sidad de células tumorales es inversamente proporcional al metabo-
lismo de la glucosa. Se han observado diferentes tendencias en las 
diferentes métricas dependiendo del estatus de supervivencia de los 
pacientes estudiados.
Parte II –  Se observa una clara mejora en la información mutua para el proceso 
de registro de imágenes cuando aplicamos el método de los gradientes 
invertidos. Este método por lo tanto, mejora el registro ayudando a una 
medida más precisa de ADC en tumores.
Parte III – a.  Es necesario un procedimiento específico y estandarizado de las condi-
ciones de adquisición de datos para un sistemático nivel de reproducibi-
lidad en estudios de DWMRI.
Parte III – b.  Cambios tempranos al tratamiento de SRS en las métricas de difusión 
y perfusión, pueden ser detectados de una manera similar a los cambios 
que se han visto por efectos de la radiación en otros estudios. La predic-
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ción de la respuesta en momentos tempranos, seria ventajosa con respec-
to a métodos que requieren largos plazos de detección en el seguimiento 
de los pacientes y ayudara a individualizar y adaptar el tratamiento ra-
dioterápico.
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Chapter I – Introduction
1. Adaptive radiotherapy based on functional imaging
Over the past 60 years, transformative developments have occurred in the practice of 
radiotherapy (RT) in oncology. These include the Cobalt-60 teletherapy unit, medical linear 
accelerators, treatment simulators, afterloading and remote afterloading techniques, radium 
and radon substitutes, computerized treatment planning, intensity modulated radiation therapy 
(IMRT) and image-guided RT, among others (1). These major technological advances have sig-
nificantly impacted the practice of radiotherapy and incrementally improved its therapeutic ef-
ficacy by more accurate dose delivery to tumors. What is needed today is a better understanding 
of a individual tumor’s response to RT that would allow a more tailored prescription. Functional 
imaging with positron emission tomography/computed tomography (PET/CT) and magnetic 
resonance imaging (MRI) have shown promise in clinical applications ranging from prognosis 
to prediction of treatment response in cancer patients (2, 3). Hence RT coupled with functional 
information is a key tool for improved treatment in radiation oncology (4, 5). This thesis will 
focus on the role of functional imaging in future adaptive radiotherapy in cancer by providing 
quantitative imaging biomarkers for individualized clinical practice in contemporary radiation 
oncology. The three novel studies that constitute this thesis are an attempt to deepen our un-
derstanding of how to manage and use valuable information derived from the above mentioned 
functional imaging modalities.
1.1.  Current functional imaging status in RT 
Today, RT techniques offer unprecedented levels of flexibility and freedom in 
treatment planning and in radiation dose delivery. These techniques – which include 
IMRT, volumetric modulated arc therapy (VMAT), and proton and heavy ion therapy – 
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enable high dose coverage of tumor volume while sparing healthy surrounding tissue, 
even allowing for the escalation of radiation dose to radioresistant areas of gross tumor 
volume (GTV) without increasing RT-induced side effects (6). 
At the same time, imaging techniques such as PET/CT and MRI have matured to 
the extent where it is now possible to better delineate the tumor volume and visualize a 
wide range of the pathophysiological characteristics of tumor, from metabolism to per-
fusion (7, 8). Diffusion-weighted (DW)-MRI provides an estimate of the diffusivity of 
water molecules in tissue, while both dynamic contrast enhanced (DCE)-CT and DCE-
MRI provide information on tissue perfusion using contrast agents (CA). On the other 
hand, PET/CT imaging relies on specific radiotracers which can be used to measure 
metabolic and functional properties of tissues. Given the scope and depth of information 
that can be made available through the integration of these imaging techniques, func-
tional imaging today presents a tremendous opportunity in furthering individualized RT 
treatment planning in cancer. 
DW-MRI and DCE-MRI both have remarkable potential in enhancing RT out-
comes (9, 10). By assessing the diffusion properties of water molecules in tissue, DW-
MRI allows to quantify voxel-based diffusion coefficients, or signal-derived quantitative 
maps of the quantitative imaging metric, apparent diffusion coefficient (ADC), which 
varies from tissue to tissue. ADC values provide valuable information about changes in 
tissue cellularity associated with tumors; as cell density increases, the ADC decreases 
as the movement of water molecules becomes more restricted. It has been reported that 
ADC has potential in characterize tumors as well as in predicting treatment outcomes 
after RT (9, 11-16). DCE-MRI, on the other hand, assesses the vascular properties of tis-
sue through a gadolinium (Gd)-based CA, which allows the acquisition of a dynamic set 
of images. DCE-MRI also has been associated with therapy response (10, 17). A recent 
clinical study confirmed that DCE-MRI data can successfully be used for response as-
sessment after therapy has been completed (18). 
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PET complements the information provided by CT and MRI techniques through 
the provision of information about the molecular and metabolic status of tumors. PET’s 
unique ability to assess molecular alterations without varying fundamental molecular 
and biochemical processes is possible due to the use of molecules (radiopharmaceuticals) 
that are labeled with radioactive nuclides. Fluorine-18 fluorodeoxyglucose (18F-FDG) is 
the most widely used radiopharmaceutical for PET studies of cancer since its invention 
in 1978 (19). As a glucose analogue, 18F-FDG concentrates in cells using glucose as an 
energy source in cellular metabolic processes; it is thus able to trace an increased depen-
dence on glucose, (i.e. an increase in glycolytic rates), a key pathophysiological altera-
tion associated with cancer cells. PET/CT’s utility in RT treatment planning, primarily in 
regards to tumor grading and staging, is widely acknowledged today (20, 21). 
Recent studies have explored the use of 18F-FDG PET/CT as a tool to enhance 
the accuracy of target volume delineation, and a large number of studies and research 
projects have developed and validated automatic and semi-automatic algorithms for the 
accurate delineation of RT target volumes based on 18F-FDG PET (7, 22). Some clinical 
trials are currently under way to test the potential of redistributing radiation dose to the 
most metabolically avid parts of tumor in non small-cell lung cancer and in head and 
neck cancer (HNC) (23, 24). Radiotracers other than 18F-FDG are also being studied 
for their role in detecting tumor hypoxia (25-27), a key factor in radiation resistance 
and of consequent significance in potential RT adaptations. These radiotracers include 
18F-fluoromisonidazole (18F-FMISO), 18F-fluoroazomycin arabinoside (18F-FAZA, and 
18F-flortanidazole (18F-HX4) (28-30). 
The combination of functional and molecular information that can be derived 
from CT, MRI and PET imaging techniques has paved the way for considerable im-
provements to the accuracy of tumor delineation and subvolume determination. Com-
plementary information obtained from functional and molecular images do not only 
improve overall accuracy in target volume delineation, but it also has led to the develop-
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ment of new tools that go beyond uniform dose delivery. Dose painting, the prescription 
and delivery of a nonuniform radiation dose to targeted volume based on molecular and 
functional images, is a relatively new paradigm in radiation oncology made possible 
by these new techniques in functional imaging, as they identify high risk tumor sub-
volumes that can be specifically targeted by higher radiation doses (31, 32). Moreover, 
RT treatment machines with MR integrated into the RT system are being tested through 
collaborative partnerships between hospitals and private medical technology vendors, 
with the imminent incorporation of these new technologies into regular clinical work-
flow (33, 34). Clinical practice in the coming years is expected to evolve - turning from 
prescribing dose to volume towards prescribing dose to optimize treatment, minimizing 
the number of tumoral cells that survive treatment with acceptable comorbidity and 
adapting RT treatment to an individualized response. This thesis will focus on the build-
ing blocks of adaptive RT for Head and Neck Squamous Cell Carcinoma (HNSCC) and 
Brain Metastases (BM).
1.2. Role of Quantitative Imaging Biomarkers in radiotherapy
In quantitative imaging, biomarkers allow information about a biological process 
to be extracted from an image; this imaged characteristic allows objective measurement 
and evaluation of a biological process, pathological process, or response to a therapeutic 
intervention, similar to laboratory or physiological assays (35). To ensure an active role 
for imaging biomarkers in future iterations of adaptive RT based on functional imaging, 
a rigorous evaluation of their technical and clinical performance is necessary. Technical 
performance for a given biomarker, or its performance in reference objects or subjects 
under controlled conditions, can form the basis for additional research to determine 
clinical validation and clinical usefulness, with the ultimate aim of determining which 
biomarkers are clinically relevant. 
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The term Quantitative Imaging Biomarker (QIB) is generally defined as ‘‘an ob-
jective characteristic derived from an in vivo image measured on a ratio or interval scale 
as indicators of normal biological processes, pathogenic processes or a response to a 
therapeutic intervention.’’ (36, 37). The standardization and optimization of quantitative 
imaging is still an ongoing process, although the Radiological Society of North America 
(RSNA)’s Quantitative Imaging Biomarker Alliance (QIBA) is developing profiles that 
provide a useful starting point for selected QIBs. For the purposes of this thesis, the fol-
lowing QIBs have been used:
1.2.1. Quantitative MRI: Diffusion-Weighted MRI and Dynamic Contrast En-
hanced MRI
Recent advances in the field of MRI include new developments in hardware, MR 
acquisition pulse sequences and MR data analysis algorithms (2, 38-40). Lately there 
has been a timely focus on Quantitative MRI (qMRI) as its utility and applications in-
crease in the clinical realm, particularly in the field of oncology. As qMRI is a technique 
to measure specific image properties, it is necessary to maximize the sensitivity, speci-
ficity and accuracy of the imaging metric in order to obtain the best possible quantifica-
tion of a specific property (2, 38-40). 
1.2.1.1. Diffusion-Weighted MRI
As mentioned above, DW-MRI measures also the Brownian movement of water 
molecules; however, the movement of water molecules is not free in the human body, 
being limited by different cells, membranes and macromolecular components.
The use of two magnetic field gradient pulses in a T2-weighted spin-echo se-
quence allow to generate MR signals sensitive to diffusion (41). These gradient pulses 
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can be tuned in duration and spacing.  The water molecules (i.e. hydrogen nucleus) 
change its location due to the process of diffusion. This movement along the gradient 
direction has two effects. First, a change occurs in the magnetic field that this nucleus 
perceives, and second, a phase shift that is proportional to the net displacement also oc-
curs. If we extend these two effects to a population of water molecules, a distribution 
of phase shifts will be obtained, resulting in a slight attenuation of the MRI signal when 
compared with hypothetical static water molecules (Fig. 1). 
Fig. 1. Schematic diagram showing a T2-weighted spin-echo sequence with two magnetic field gradient 
pulses of strength G, duration δ, and spacing Δ (diffusion-weighted spin-echo sequence), applied to a 
group of static and moving water molecules. The moving water molecules are affected showing a loss 
of signal respect to the static group. Water diffusion is detected as attenuation of measured MR signal 
intensity.
The signal attenuation is precisely and quantitatively connected to the amplitude 
of the displacement distribution (2, 42). The tuning of the magnetic field gradient pulses 
through the b-value, a factor that reflects the strength and timing of the gradients, gener-
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ates different degrees of diffusion sensitivity as illustrated in Fig. 2. The common pulse 
sequence in clinical settings for DW-MRI is the Single-shot Spin-echo Echo Planar Im-
aging (SSEPI) (43).
Fig. 2. Diffusion-weighted images of a brain metastasis located in the right occipital region of the brain 
in a patient. The MR signal is attenuated with the increasing b-values (0, 20, 50, 80, 200, 300, 500, 800, 
1500, 2000 s/mm2).
The attenuation of signal intensities in diffusion-weighted images with different 
b-values allows for the estimation of the diffusion coefficients in each image location 
(voxel) through appropriate model fitting (Fig. 3).
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Fig. 3. Diffusion-weighted signal intensity versus b-value in a brain metastasis patient, exhibiting the 
non-monoexponential decay behavior. The graph illustrates typical in vivo signal attenuation of DW-
MRI.
The monoexponential model considers biological tissue as one compartment. The 
metric that we estimate from this model is the ADC. There are biophysical properties 
that have an influence on the mobility of water molecules in tissue. Tumors have lower 
values of ADC than benign tissues because cells in tumors are more tightly packed; in 
other words, water diffusion is more restricted in tumors because malignant tissues have 
more chaotic tissue organization and greater cellular density than benign tissues. 
An example of the bi-exponential model is the intravoxel incoherent motion (IVIM) 
introduced by Le Bihan. This model considers biological tissue as two compartments: 
intra-vascular and extracellular space having the same diffusion and magnetic relaxation 
properties as depicted in Fig. 4 (42). IVIM measures the Brownian water molecular dif-
fusion and capillary perfusion and estimates the quantitative imaging metrics: D (i.e., true 
diffusion coefficient (mm2/s)),  blood perfusion fraction in capillary networks through f 
(i.e., vascular volume fraction or perfusion factor), and D* which is the pseudo-diffusion 
coefficient (mm2/s) associated with blood flow and capillary geometry (42).
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Fig. 4. Schematic diagram depicting different compartments at a voxel level in the tissue. IVIM model 
consider two compartments extra- and intra-cellular space. The D, D* and f represent the true diffusion 
coefficent, pseudo-diffusion coefficent and perfusion factor.
1.2.1.2. Dynamic contrast-enhanced MRI
DCE-MRI provides a measurement of tissue perfusion through the acquisition of 
fast high-temporal T1weighted (w) MR images before, during, and after the administra-
tion of a small paramagnetic contrast agent (CA) like gadolinium-diethylenetriamine 
pentaacetic acid (Gd-DTPA). Fig. 5 exhibits the standard T1w and T2w images along 
with DCE-MRI images in a patient with a brain metastasis.
Fig. 5. Representative MRI images of a patient with a brain metastasis: Axial T1w, T2w, DCE-MRI im-
ages during 1st and 20th time course data points.
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Biological tissue contains intravascular, extracellular or interstitial, and intracel-
lular compartments. Water exchange between erythrocytes and plasma is fast on the MR 
time scale; thus, the intravascular pool is considered a single compartment. Following 
intravenous administration, CA leaks through the intravascular compartment to the ex-
tracelluar space by passive diffusion in tumors, altering signal intensity of the tissue by 
changing the relaxation rates of water protons.  
The extended standard model (i.e. also called Toft’s) (44, 45) , based on the de-
cades old single capillary model (46), utilizes the contrast agent concentration in blood 
plasma, also called the arterial input function (AIF), to estimate Ktrans - volume transfer 
constant between intravascular and extracellular space, ve - extracellular volume fraction 
and vp - plasma volume fraction. The rate constant from extracellular to intravascular 
space (kep) is related to Ktrans/ve (Fig.6). 
Fig. 6. Schematic illustration of three compartments: intravascular, extra- and intracellular space. Ktrans is 
volume transfer constant from intravascular to extracellular space; kep is the rate constant from extracel-
lular space to intravascular space; vp and ve are the volume fraction of plasma and extracellular space, 
respectively. 
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A T1w spoiled gradient recalled echo (SPGR) sequence is commonly used in 
clinical setting to acquire DCE- MRI data.  The DCE-MRI signal-versus-time curves for 
artery and tumor, obtained from a BM patient are shown in Fig. 7 and 8.
Fig. 7. Signal intensity over time curve extracted from the middle cerebral artery of a BM patient follow-
ing bolus injection of CA.
Fig. 8. Signal intensity over time curve extracted from the tumor of a BM patient following bolus injec-
tion of CA.
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1.2.2. Quantitative PET/CT: Fluorine-18 Fludeoxyglucose 
PET imaging technology has been in clinical use for more than 2 decades, with 
oncology a major focus of its application. This technique has the ability to provide unique 
information about the molecular and metabolic changes associated with tumors, using 
molecules labeled with radioactive nuclides such as 18F-FDG (Fig. 9) (19). FDG follows 
the glucose pathway from plasma to tissue, remaining trapped in the tumor cell (19). The 
positron emitted by 18F at this location annihilates with a nearby electron, creating two 
simultaneous gamma rays that travel in almost opposite directions through a ring of PET 
scanner detectors. Following the paths of these two gamma rays, we can determine the 
approximate location at which the annihilation occurred, thus obtaining a highly sensi-
tive measurement of the distribution uptake of 18F-FDG as illustrated in Fig. 9 (47). This 
highly sensitive image generated by PET can lack adequate anatomical information. 
The use of a combined PET/CT with the precise co-registration of the functional (PET) 
and anatomical (CT) studies gives extra information to localize the tumor with greater 
precision, as shown in Fig. 9 (48). The quantitaive imaging metric, Standard Uptake 
Value (SUV), is used in 18F-FDG imaging to try to normalize the uptake for administered 
activity, radioactive decay from time of administration, and patient body mass. SUV is 
considered an approximate index of 18F-FDG uptake, and can be affected by such factors 
as the physiological state of the patient, patient body composition, size of the lesion, mo-
tion (such as respiratory motion), and region of interest (ROI) selection (49).
Fig. 9. a. Diagram showing the basic process of the positron emission and annihilation with the subse-
quent emission of two gamma rays detected by the PET scanner detectors (adapted from (50, 51)). b. 
Structure of 18F-FDG. c. Coronal PET image showing the uptake (black spot) of a neck nodal metastasis 
in HNSCC patient. d. Axial CT image of the HNC region. e. PET/CT image of a neck nodal metastases 
(red arrow) showing the uptake of 18F-FDG.
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1.2.3. Clinical application of Quantitative Imaging Biomarkers in treatment re-
sponse assessment and prognosis
DW-MRI, DCE-MRI and 18F-FDG PET/CT have clinical applications ranging 
from characterization of tumor to prediction of treatment response (40, 49, 52). This the-
sis will focus on QIBs in treatment response assessment and prognosis estimated from 
multimodality imaging in HNSCC and BM.
1.2.3.1. Head and Neck Squamous Cell Carcinoma 
HNC are usually treated with surgery or chemo-radiation therapy (CRT) depend-
ing on the extent of the disease (53). DW-MRI estimated ADC constitutes as a biomark-
er for CRT response in HNSCC. In most cases, high pre-treatment (Tx) ADC values for 
a tumor reflect a worse response to treatment in comparison to tumors with lower pre-Tx 
ADC values. The necrotic area inside the tumor could be one possible explanation of 
this biological behavior (54). Increasing ADC values during or after treatment when 
compared to pre-Tx values generally reflect that the treatment is successful (2, 11). 
A study by Hauser et al. using IVIM DW-MRI indicates that higher f values may 
predict poor prognosis in HNSCC; additionally they demonstrate a significant increase 
of all IVIM parameters after CRT (55). Overall, an increase in diffusion related pa-
rameters such as ADC and D is correlated with good outcomes. Kim et al. have shown 
that a significant increase in ADC was observed within 1week of treatment in HNSCC 
patients who were complete responders (p-value < 0.01) (11). Vandecaveye et al. study 
further established the utility of ADC in differentiating responding from non-responding 
HNSCC by providing a threshold (25% and 20% for primary tumors and lymph node 
metastases, respectively) for the percent relative (Δ) ADC change between pre-Tx and 
3 weeks post-Tx (56). 
DCE-MRI has shown promise in prognosis of HNSCC. A study by Shukla-Dave 
et al. suggests that high skewness of Ktrans was observed in HNSCC patients with poor 
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prognosis (10). Usually heterogeneous tumors in head and neck region are associated with 
hypoxia and necrotic areas (57). Chawla et al. found significantly lower Ktrans in non-re-
sponders compared to responders in neck nodal metastases of HNSCC patients (54).
A high SUV value reflects increased glucose uptake in most primary tumors and neck 
nodal metastases (58). 18F-FDG PET/CT has an established role in HNSCC management 
including staging and monitoring CRT response (59, 60). Schwartz et al. study showed that 
primary tumor SUV was a promising prognostic factor in HNSCC patients (61). 
1.2.3.2. Brain Metastases 
In radiation oncology, the use of stereotactic radiosurgery (SRS) for treatment of 
metastatic intracranial disease has grown in popularity due to its increasing ease of use, 
the avoidance of cognitive side effects related to whole-brain (WB) RT, and its inclusion 
as a treatment option in clinical trials (62, 63). The average reported survival of patients 
with SRS-treated BM is 6–8 months. Within this timeframe, studies have shown SRS 
to achieve a high radiographic lesional control rate, defined as lesions with stable or 
decreasing size (64, 65). Lesion control rates are reported to vary by time since treat-
ment, pathology, and lesion size measurements (66, 67). However, no single study has 
looked at all of these factors during follow-up imaging. In clinical practice, increases in 
radiographic lesion size post-SRS raises the question of treatment failure versus radia-
tion injury, resulting in difficulties with patient management. This clinical question is 
more relevant than ever as many patients with BM treated with SRS are living for much 
longer periods of time with recent advances in systemic therapy. Many studies have 
reported variable degrees of diagnostic sensitivity and specificity using various MRI 
sequences and PET imaging techniques, although they have not led to a consensus (68, 
69).  The existing literature on the assessment of BM with MRI after SRS is sparse and 
even scarcer for advanced quantitative imaging in this setting (64, 70-73). Furthermore, 
there are no studies that assess response after SRS within 72 hours or less.
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1.3. Advanced Radiation therapy treatments in Cancer
1.3.1. Intensity-modulated radiation therapy 
IMRT aims to sculpt radiation dose in such a way that prescribed dose is deliv-
ered to the tumor while healthy tissue is spared from unnecessary radiation exposure 
(74). The procedure manipulates the intensity of each part of a radiation beam for greater 
precision in tumor irradiation, and allows the use of multiple beams of differing sizes 
and intensities during treatment. By modulating the intensity of a radiation beam, one 
or many areas or high intensity radiation and low-intensity areas may exist within a par-
ticular field, providing improved control over dose distribution. Furthermore, a radiation 
beam can be broken up into “beamlets” whose intensity may be individually adjusted. 
With an expanded range of tools with which to control both the number of fields and 
the intensity of radiation within a field, dose distribution can be sculpted with increasing 
precision to conform closely to target volume; IMRT has thus proven capable of “paint-
ing” a dose around critical healthy tissues despite complex target and critical structure 
geometries. 
1.3.1.1. Head and Neck Squamous Cell Carcinoma in Spain
The Spanish Cancer Registries reported that in 2014, 241,284 new cases of can-
cer were diagnosed in Spain (75). Out of these, 12,696 were HNC and approximately 
90% were SCC (76). Oropharyngeal SCC was the main subgroup for these patients and 
52-72% was caused by infection with human papillomavirus (HPV) (77). It has been 
previously reported that HPV negative (-) HNSCC have poor outcomes compared to 
HPV positive (HPV+) cancers (78). The mainstay of treatment worldwide for HNSCC 
remains concurrent CRT and/or surgery (53, 58), with IMRT as an ideal RT technique to 
minimize side effects and increase local tumor control
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1.3.2. Stereotactic Radiosurgery
SRS is a non-invasive, highly precise form of RT that aims to destroy tumor 
through targeted, high-dose radiation and to achieve local control (62). Because dose 
delivery is accurate to within one to two millimeters in SRS, the procedure is capable 
of delivering maximum dose within a target while minimizing the exposure of healthy 
surrounding tissue to ionizing radiation. To achieve this level of precision, SRS relies 
on 3-D imaging techniques such as CT, MRI, and PET/CT to determine a tumor’s exact 
size, shape, and location within the patient, immobilization systems to ensure proper 
patient positioning and fixation throughout the therapy, highly focused gamma-ray or 
x-ray beams, and IGRT to confirm a tumor’s location before and sometimes during treat-
ment. SRS is usually a one-day treatment, but multiple stereotactic treatments may be 
recommended in certain circumstances, as for tumors larger than 2.5cm in diameter. 
As a non-invasive procedure, SRS also has implications for patients who are unable to 
undergo surgery. 
1.3.2.1. Brain Metastases in the United States of America
A common neurological complication of cancer, BM affect approximately 20-
30% of all cancer patients in the United States (79, 80). These metastases are from 
primary tumors originating in lung (50 %), breast (15% to 20%) and melanoma (10% to 
15%). In some cases (10% to 15%) the primary site of the tumor maybe unknown. Lung 
cancer and melanoma are frequently associated with multiple metastases while breast 
and renal cancers are mostly related with single metastasis (81).
The incidence of BM has been on the rise, a trend often attributed to improve-
ments in imaging techniques that allow for earlier detection, as well as to improvements 
in treatment that have helped prolong the life of many cancer patients. In 2007, 1.5 
million patients in USA received a primary diagnosis of cancer, with about 5% of these 
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primary diagnoses estimated to relapse in the brain (79, 82). BM are an important cause 
of mortality (83). In terms of treatment options, SRS has emerged as one of the most 
important for the management of these tumors. BM are also ideal targets for SRS due 
to characteristics conducive to accurate target delineation, planning, and dose delivery. 
These tumors are usually largely spherical with a maximum diameter of less than 4 cm, 
and located in the gray-white junction. Unlike primary gliomas, BM are non-infiltrative, 
making the highly precise techniques of SRS a viable and effective means of therapy 
with a high local control rate, defined as lesions with stable or decreasing size (64). 
Despite these factors, which point to the relevance of BM and its treatment in radiation 
oncology, prospective studies in RT treatment involving patients with BM are limited.
1.4. Challenges of intensity-modulated radiation therapy and stereotactic radio-
surgery in adaptive radiotherapy based on functional imaging
Three major technical challenges in IMRT and SRS persist in the use of func-
tional images for RT: identifying a reproducible, radiotherapy-compatible patient posi-
tion that is consistent between functional techniques and RT; furthermore, issues related 
to spatial resolution, geometrical accuracy and standardization and reproducibility also 
constitute challenges. This thesis addresses the above challenges in RT based on func-
tional imaging. 
1.4.1. Patient positioning
In order to ensure precise dose delivery, it is essential for patient positioning to 
remain the same throughout the treatment simulation and delivery process, which can 
last several weeks. In Meixoeiro University Hospital of Vigo, Spain, the HNSCC pa-
tients were scanned using the same immobilization device as in RT and a flat table for 
multimodality imaging to reduce issues related to patient positioning. 
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While the reproducibility of patient position poses fewer inherent difficulties for 
CT, differences in the practice of patient positioning between MRI and RT presents 
additional challenges. In treatment planning and delivery that relies on the CT scan or 
PET/CT scan, for example, the linear accelerator of the treatment room is set up to copy 
the frame of reference established by laser systems in the CT or PET/CT room. Further-
more, wide-bore CT scanners have made it possible to scan patients in the treatment 
position, with patients lying on a flat bed design typical of a radiotherapy simulator or 
treatment couch, allowing for a consistently reproducible patient position from planning 
through delivery. When MRI is used in RT planning and delivery, however, additional 
considerations come into play. MRI scanners, which typically place body phased-array 
coils around the patient and tend to be designed to maximize patient comfort due to the 
duration of the study, must be adapted to mimic the flat bed design of the RT treatment 
table and suitable for RT positions. Any immobilization devices that will be used for 
other imaging devices or for treatment – such as a stereotactic head frame – must be 
assessed for magnetic safety as well as their ability to fit in the scanner without interfer-
ing or disrupting the placement of MR coils. Typical RT practice in patient positioning 
for different types of cancers must also be considered from the onset, from the use of 
stereotactic frames (HNC) or wedge-shaped supports (breast cancer) to the placement of 
the patient in prone or supine position. Solutions to these challenges often compromise 
image quality because they reduce signal-to-noise ratio (SNR) performance due to the 
way they interfere with the conductivity of the radiofrequency coils used in MR: for 
example, the flat bed design of RT is often reproduced in MRI by laying a thin insert on 
top of the coils, which creates a gap between the patient and the coils that can reduce 
SNR. Furthermore, the fixation mask used to guarantee reproducible orientation and 
neck flexion in the treatment of HNC does not fit in most coils used for HN MRI. While 
the attachment of flexible surface coils to the surface of the mask has been proposed as a 
possible solution, new methods to incorporate RT masks into systems using multichan-
nel head coils for quality imaging need to be further identified (84, 85).
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Given these constraints, it may not be feasible to undertake imaging in a re-
producible RT position. Furthermore, anatomical changes often occur in a patient as a 
response to therapy: normal tissues may deform, and tumor volumes may shrink. With 
the growing emphasis on the personalization of treatment, a re-contouring of the region 
of interest (ROI) for re-planning or to measure dose accumulation is often necessary at 
varying time points, posing new challenges in image registration. In order to ensure the 
alignment of information obtained from different imaging modalities at the voxel level, 
it is necessary to use dedicated methods for deformable image registration (DIR) (86, 
87). DIR is a relatively new method capable of aligning corresponding points derived 
from different imaging techniques and constitutes an important tool in image registra-
tion for multimodality functional imaging. Yet DIR algorithms have limited availability 
outside the research setting, and still lack clinical validation.
1.4.2. Spatial resolution and geometrical accuracy
Distortions are an issue in both PET/CT and MRI, and they range from suscep-
tibility artifacts to geometric distortions.  This thesis will focus only on evaluating and 
correcting the distortions related to diffusion acquisition sequences, in an experience at 
Meixoeiro University Hospital of Vigo, Spain.
Tumor delineation based on MRI relies on good spatial resolution and geometri-
cal accuracy, without which tumors can remain undertreated or healthy tissue exposed 
to unnecessary radiation. While advances in technology and technique have led to im-
provements in both areas, fundamental challenges remain. With advances in IMRT, dose 
delivery has become precise to the order of a millimeter, making accurate tumor delinea-
tion an essential factor in treatment planning. The T2w spin echo sequences most often 
used by MRI for tumor delineation, however, result in slices that are much thicker, at 3 
mm or more, which imposes an implicit limit; furthermore, PET/CT has a similar spatial 
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resolution. In addition, geometrical distortions caused by nonlinearities and eddy cur-
rents in gradient coils or inhomogeneities in the main magnetic field (B0) provide inac-
curate spatial information and hinder accurate image correlation. Because the homoge-
neity of the static magnetic field (B0) decreases as distance from the center of the magnet 
bore increases, some of the distortion is a natural property of MR scanners; these sys-
tem-related distortions can be corrected through lookup tables derived from phantoms. 
Object- and patient-induced distortions, however, cannot be readily corrected through 
the use of phantoms. Object-induced distortions include those arising from magnetic 
susceptibility and chemical shift effects. Distortion resulting from magnetic suscepti-
bility is particularly pronounced at air and tissue transitions, i.e. at the boundaries of 
structures with different magnetic susceptibilities (88, 89). Chemical shift effects are 
caused by the differences in resonance frequencies between protons in fat and those in 
water. While increasingly sophisticated correction techniques continue to be developed 
for these distortions, the correction of realistic images can be difficult. These distortions 
can be visualized, however, by using gradient reversals, or by comparing images with 
opposite readout gradient directions; by mapping the two images acquired through such 
a procedure, the correction of images of human anatomy may be achieved (90). In DW-
MRI, the standard practice of collecting imaged volume through echo planar imaging 
(EPI) is vulnerable to distortions associated with EPI sequences, which can make cor-
rection even more difficult. EPI exhibits strong distortions in the direction along which 
k-space is traversed slowly, i.e. the phase encode (PE) direction (91, 92). While the size 
of the PE gradient can be modified by using the bandwidth parameter (as maximizing 
bandwidth can reduce distortion, which is the case in parallel imaging), distortions can 
remain large in close proximity to air-tissue boundaries. In HNSCC an alternative to 
EPI could be half-fourier acquisition single-shot turbo spin-echo (HASTE)  which has 
shown less geometric distortion than EPI (93). Although, a recent study by Schouten et 
al. suggests that HASTE seems to be inadequate in early response to treatment in HN-
SCC when is compared to EPI-DWI (94).
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Due to the importance of spatial accuracy in radiation oncology treatment planning 
and delivery, the minimization of geometrical distortions remains a priority. One of the 
aims of this thesis is therefore dedicated to correcting these geometrical distortions in MRI 
for the purposes of adaptive RT based on functional imaging for HNSCC patients. 
1.4.3. Standardization of imaging  protocols and reproducibility of Quantitative 
Imaging Biomarkers
Standardization of organ-specific imaging protocols is important for DW-MRI, 
DCE-MRI and 18F-FDG PET/CT.  RSNA/QIBA is presently generating DW-MRI, DCE-
MRI and 18F-FDG PET/CT profiles which will help in the worldwide translation of 
these techniques and will be available for public viewing at RSNA website. However, 
experiments need to be performed to establish the repeatability and reproducibility of 
the imaging techniques. RSNA/QIBA has defined these terms as follows (36):
Repeatability: Repeatability represents the measurement precision under a set of repeat-
ability conditions of measurement.
Repeatability condition of measurement: The repeatability condition of measurement is 
derived from a set of conditions that includes the same measurement 
procedure, same operators, same measuring system, same operating 
conditions and same physical location, and replicate measurements 
on the same or similar experimental units over a short period of time
Reproducibility: Reproducibility is measurement precision under reproducibility condi-
tions of measurement.
Reproducibility condition of measurement: The reproducibility condition of measure-
ment is derived from a set of conditions that includes different loca-
tions, operators, measuring systems, and replicate measurements on 
the same or similar objects.
–  24 –
In this thesis, the DW-MRI was used as a test model to perform repeatability and 
reproducibility experiments using the ice-water phantom constructed by Chenevert et 
al. (95). This part was initiated at Memorial Sloan-Kettering Cancer Center (MSKCC), 
USA.
The standardization of 18F-FDG PET data acquisition and analysis continues to 
be a priority; while recommendations for standardization have been published by various 
bodies, they have yet to be adopted by or fully implemented in the clinical flow (49, 96).
There is a lack of standard approaches for data collection and analysis in DW-
MRI and DCE-MRI to implement them as imaging biomarkers of treatment response 
in routine clinical practice. This needs to be addressed by performing prospective, large 
patient population validation studies between multi-centers and multi-vendors. The lim-
its of technology and patient compliance are the main reasons for this lack. Standard 
methods of assessment should be established and validated against phantoms, with their 
measurements of reproducibility also being established in multi-center settings. For ex-
ample, the absence of a standard, repeatable, and consistent methodology for QIBs, the 
ambiguities that remain in the interpretation of voxel-based data can lead to drastic dif-
ferences in target volumes for irradiation. 
As there is a lack of consensus in the approach to DW-MRI data collection and 
analysis, it has been difficult to implement the technique extensively worldwide. The 
lack of standardization, in turn, has made it more challenging for commercial MRI ven-
dors to support DW-MRI, and has limited the use of DW-MRI to sites with sufficient 
experimental MRI expertise to tackle its complexities. 
Technical challenges in acquiring DW-MRI data often make it impractical to per-
form “ideal” data acquisitions, necessitating compromises in acquisition and/or analysis. 
Reducing the number of b-values for modeling of data, limiting volume of imaging and 
reducing spatial resolution are some examples.
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In addition to the standardization of methods of diffusion assessment, their measure-
ment reproducibility should also be established. In fact, it is necessary to demonstrate the re-
producibility of all clinical measurements undertaken at centers, both at the individual and 
intergroup levels, in order to facilitate study design and to assess the significance of change. By 
using this information in conjunction with the expected magnitude of therapeutic effect, studies 
will be able to assess dose-related change. 
Reproducibility and repeatability assessments need to be done for organ-specific protocols and 
sources of error need to be determined and corrected before initiating a clinical trial. DW-MRI 
clinical trials that assess response to treatment need to include an assessment of measurement 
variability as a key part of their trial design. The measurement error estimate component needs 
to be performed on enough study patients or patients representative of those in the study to 
be statistically relevant. Similar statistical methods should be used across diverse anatomic 
sites and pathologies to allow for comparative analyses, with a common understanding of the 
meaning and limitations of statistical measures. There is a common interest in standarize the 
DW-MRI sequences and the methods to calculate the metrics. Malyarenko et al. reported that 
standardization of the data acquisition conditions improved the reproducibility of ADC mea-
surements (97). Recently Kolff-Gart et al. in a prospective study with 7 healthy subjects as-
sessed the reproducibility of ADC values with different MRI systems, sequences and anatomi-
cal sites in the head and neck region. The study concluded that a small variance in ADC values 
occurred if the subject is measured on the same MRI system and with the same sequence (98). 
Assessment of reproducibility and repeatability should be a performed as part of imaging pro-
tocols for integration of QIBs in adaptive RT (2).

Chapter II
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Chapter II: Motivation, Hypothesis and Objectives
This Ph.D. thesis is divided into three parts; the order of the parts is in accordance with 
the chronology of the development of this thesis, with the three parts connected in terms of 
motivation and objectives. The studies in Part I and Part II were performed at Meixoeiro 
University Hospital of Vigo, Spain. The study in Part III was conducted at Memorial Sloan-
Kettering Cancer Center, USA.
2.1. Part I: ARTFIBio project: A novel framework for adaptive radiotherapy based 
on functional images - Experience at Meixoeiro University Hospital of Vigo, Spain
Motivation: In the modern era of adaptive RT, it has become vital to understand how dif-
ferent functional imaging techniques interact and link together in tumors. 
DW-MRI and 18F FDG PET/CT are two valuable imaging techniques that 
may help build the framework for future adaptive radiotherapy based on 
functional imaging.  This was the motivation of Part I of the thesis.
Hypothesis:  DW-MRI will aid in measuring tumor cellularity while 18F FDG PET/CT 
will measure the glucose metabolic uptake for both the primary tumors and 
neck nodal metastases in HNSCC.
Objective:  To noninvasively investigate tumor cellularity measured using DW-MRI 
and glucose metabolism measured by 18F-FDG PET/CT during CRT for 
human papillomavirus negative (HPV-) head and neck squamous cell car-
cinoma (HNSCC).
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2.2. Part II: Novel application of the reversed gradient Diffusion-Weighted MRI 
method for tumor response assessment in head and neck cancers (including 
the novel design of a Phantom Distortion Assessment) - Experience at Meix-
oeiro University Hospital of Vigo, Spain
Motivation:  With the onset of precision medicine in oncology, there is an urgent need 
to assess tumor response during treatment using functional imaging. How-
ever, the implement of these functional techniques in routine clinical work 
flow is one of the most challenging issues in radiation therapy. One con-
stant challenge is to improve image quality and reduce distortion to obtain 
quality images for radiation treatment planning and delivery. This part of 
the thesis applied the reversed gradient method in DW-MRI to obtain ac-
curate ADC measurements and minimize geometric distortions in images. 
Hypothesis:  Reversed gradient method in DW-MRI will help reduce geometric distor-
tions and improve measurement accuracy for quantitative imaging metric 
ADC.
Objective:  This study investigates the use of the reversed gradient method in DW-
MRI for reduction in geometric distortion and measurement of accurate 
ADC, a biomarker of treatment response. Geometric distortion correction 
will be assessed using mutual information metrics from registration pro-
cesses used in radiation therapy treatment.
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2.3. Part III: Intra Voxel Incoherent Motion Diffusion Weighted MRI and Dynamic 
Contrast Enhanced MRI methods for tumor response assessment in Brain Metas-
tases – Experience at Memorial Sloan-Kettering Cancer Center, USA
Motivation: There are some cancer patients that do not go into remission after treatment. 
One of the clinical problems lies in the management of patients with BM. 
SRS is one of the options for these patients to either stabilize the disease 
or prevent further progression of disease. Hence, in clinical settings it is 
extremely essential to accurately assess, whether or not a brain metastasis 
has been successfully treated or whether the metastasis requires additional 
treatment. This was the motivation for Part III of the thesis. In order to 
ensure accurate assessments of BM in the clinical scenario, quantitative 
imaging biomarkers may play a crucial role in deciphering early on treat-
ment efficacy. Hence, a basic prerequisite is having reliable and robust 
quantitative imaging biomarkers.  In the present study, IVIM DW-MRI 
and DCE-MRI were performed both pre- and post- (1-72 hours) SRS. 
Hypothesis: Early changes in perfusion and diffusion derived quantitative imaging met-
rics will inform the treating physicians at an early time point about which 
patients will benefit from SRS (or not). For example, metric D (true diffu-
sion coefficient), will increase and metric Ktrans (volume transfer constant) 
will decrease with effective SRS treatment.
Objective:  To determine whether quantitative imaging metrics derived from IVIM DW- 
and DCE- MRI can assess early treatment response in patients with BM 
treated with SRS.

Chapter III
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Chapter III: Material & Methods
3.1. Part I: ARTFIBio project: A novel framework for adaptive radiotherapy based on 
functional images - Experience at Meixoeiro University Hospital of Vigo, Spain
3.1.1. Patients
This prospective study was conducted in accordance with the Declaration of Helsinki 
(99) and the study protocol was approved by the local ethics committee; informed consent was 
obtained from all patients. All patients eligible for this study had biopsy-proven newly diag-
nosed HNSCC; and diagnostic biopsies were tested for HPV status. Six HPV- HNSCC patients 
underwent a total of 34 multimodality imaging (DW-MRI imaging studies at 1.5 T Philips 
MRI scanner (n=24) pre-, during (2-3 weeks) and post-CRT and 18F-FDG PET/CT pre- and 
post-CRT (n=10)). All of the patients were treated with IMRT and the prescribed dose varied 
between 66 Gy and 70 Gy to the local planning target volume (PTV). Patient characteristics are 
given in Table 1. 
All patients had a clinical follow-up as the standard of care and survival status was 
documented into groups at 1 year. The four groups for patients were as follows: no evidence 
of disease (NED), alive with disease (AWD), dead of disease (DOD) and dead of other causes 
(DOC). Additionally, locoregional and distant metastases status was noted for all patients (100).
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Table 1. Characteristics of the HNSCC patients involved in 
this study.
Characteristics Value
Total patients 6
Demographics
Mean age (yr) 65
Age Range (yr) 52-79
Male/Female 5/1
Location of Primary tumor
Oropharynx 6
Metastatic loco-regional Nodes 11
Radiation Therapy technique IMRT
Dose (Gy) 66-70
Fractions 32
Outcome
Alive with disease (AWD) 3
Dead of Disease (DOD) 2
No evidence of disease (NED) 1
3.1.2. Design of the study
All the patients recruited in this study underwent the workflow designed for the 
ARTFIBio project as we shown in Fig. 10.
A total of 34 multimodality imaging studies were performed (24 MRI and 10 18F-
FDG PET/CT exams) were performed according to the following timeline: 
•	 Pre treatment: MRI study (T1w, T2w, and DW-MRI) and 18F-FDG PET/CT study. 
•	 During treatment: MRI study (T1w, T2w, and DW-MRI) at 2 time points.
o First time point :10 - 30 Gy [1-2 weeks during treatment]
o Second time point: 30 Gy – 60 Gy [3-4 weeks during treatment]
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•	 Post treatment: MRI study (T1w, T2w, and DW-MRI) and 18F-FDG PET/CT 
study.
Fig. 10. Workflow representing the ARTFIBio project that was used for all the HNSCC patients at Meix-
oeiro University Hospital of Vigo, Spain.
3.1.3. Image acquisition protocols
3.1.3.1. Diffusion Weighted MRI
All MRI examinations were performed on a Philips 1.5-Tesla scanner (Achieva; 
Philips Healthcare, Netherlands) with a Philips Sense Flex coil over the neck at Meix-
oeiro University Hospital of Vigo, Spain. For MRI, all patients were in supine position 
and fixed with the immobilization system which was also used during the radiotherapy 
treatment delivery (Fig. 11). A thermoplastic mask, head support and flat table were used 
to try to minimize the distortion and to improve the registration process between the dif-
ferent imaging modalities. The head support and flat table were adapted to MRI/safety 
requirements. The MRI protocol consisted of the standard anatomic MRI scans (T1w/
T2w images) and DW-MRI.
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DW-MRI acquisition was performed using a SS-EPI with 3 b-values (b=0; 600 
and 1000 s/mm2). Other parameters included repetition time (TR) = 5000 ms; echo time 
(TE) = 77-100 ms, number of excitations (NEX) = 2, field of view (FOV): 25 cm; and 
slice thickness=6 mm. The total acquisition time for obtaining the DW-MRI data was 
approximately 5 minutes. The acquisition matrix of 120x97 was zero filled to 256x256 
during image reconstruction.
Fig 11. a. Flat table with head support adapted to MRI-safety requirements. b. Illustrates the patient po-
sitioning with the thermoplastic mask over the head support and flat table adapted to MRI-safety require-
ments.
3.1.3.2. Fluorine-18 Fludeoxyglucose PET/CT
A whole-body PET/CT scan was performed from head to thigh, 60 min after in-
travenous administration of approximately 370MBq (±10%) of 18F-FDG on a PET/CT 
scanner (Discovery, GE Healthcare Bio-Sciences Corp, Milwaukee, WI) at Meixoeiro 
University Hospital of Vigo, Spain. The patient was placed in supine position, with the 
same immobilization system as in the radiotherapy treatment delivery (Fig. 12). Other 
parameters included a 70 cm axial FOV, a 218 × 218 matrix. Data was acquired in 3D 
mode. The pixel spacing was 5.47 mm with a slice thickness of 3.27 mm. The spatial 
resolution to 1 cm varies from 3.99 mm to 4.56 mm. PET images were corrected for at-
tenuation, scatter, decay, dead time, random coincidences, and slice sensitivity. 
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Fig. 12. a. Flat table with head support adapted to PET/CT requirements. b. Illustrates the patient position-
ing with the thermoplastic mask over the head support and flat table at the PET/CT.
Table 2. DW-MRI and Whole body PET/CT scan parameters.
MRI (Philips 1.5T) DW-MRI PET/CT (Discovery; GE) Whole-body PET/CT
Sequence SS-EPI Mode 3D
TR (ms) 5000 FOV (cm) 70
TE (ms) 77-100 Slice thickness (mm) 3.27
NEX  2 Pixel Spacing (mm) 5.47
FOV (cm) 25 x 25 18F-FDG 370 MBq
Slice thickness (mm) 6 Corrections attenuation, scatter, de-
cay, dead time, random 
coincidences and slice 
sensitivity
b-values (s/mm2) 0, 600, 1000
Acquisition Matrix 120RL x 97AP
3.1.4. Image analysis
All images were registered and analyzed using in-house software (101). The reg-
istration process for DW-MRI and 18F-FDG PET/CT datasets was a two-step process: 
1) Manual registration: performing a manual alignment (translation and/or rotation) of 
the images (DW-MRI; CT-Scan; PET/CT) interactively on screen. 2) Automatic Rigid 
Registration: Once the images were approximately aligned, a more precise alignment 
(full rigid transformation) was performed based on an iterative process evaluated by 
statistical metrics (viola-wells mutual information (102)). Using the Artfibio-tool, the 
signal intensity values were extracted from the whole tumor volumes (101).
–  40 –
3.1.4.1. Diffusion Weighted MRI
According to Stejskal & Tanner’s work (41) and considering the monoexponen-
tial approximation (103), the ADC value is calculated using Eqn.1:
 = ( ) ; = 1:    [1]
Where S0 is the signal intensity without diffusion weighting,  represent the signal 
intensity with the diffusion weighting factor, b is the b-value (s/mm2), subindex i repre-
sents the different b-values.
ROIs were delineated on the primary tumor and neck nodal metastases by an 
experienced neuro-radiologist on the DW-MRI image (b = 0 s/mm2). Before contouring 
the ROIs, the T2w/T1w images were used to determine localization and tumor extent.
Finally, a relative percentage change in estimated imaging metric ADC between 
pre- and ith intra-Tx week (Wk) was calculated as follows (Eqn.[2]): 
 
∆ ( %) = ( )  100  
   [2]
Where subindex i represents intra-Tx week for ADC metric value and ADC0 rep-
resents the pre-Tx metric value.
3.1.4.2. Fluorine-18 Fludeoxyglucose PET/CT 
A radiation oncologist matched the ROIs from the MR images with those of the 
PET/CT images and analyzed them qualitatively and quantitatively using the attenua-
tion corrected PET emission images. The ROIs were placed over the areas of focal 18F-
FDG uptake in both the primary tumor and neck nodal metastases. The intensity of the 
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18F-FDG uptake in the ROIs was measured using the SUV normalized by the dilution 
volume (104) as shown in Eqn.[3]: 
 SUV =
        
 /  
    
[3]
The imaging data available in units of µCi/mm per voxel were decay corrected to 
the time of injection and converted to SUV units (105).
3.1.5. Statistical analysis
In the present study, data was analyzed from a total of 34 multimodality im-
aging (DW-MRI imaging studies (n=24) pre-, during (2-3 weeks) and post-CRT and 
18F-FDG PET/CT pre and post treatment (n=10)) to capture treatment response. Values 
were presented as mean ± standard deviation. A Spearman correlation analysis was per-
formed between SUV and ADC metric values in the pre-Tx time point, prior to any treat-
ment, allowing analysis of the correlation between to imaging parameters without the 
potentially confounding effects of treatment. Correlations were reported as in standard 
guidelines  with p-values and correlation, in which an absolute correlation of <0.3 was 
considered weak, 0.3-0.5 were considered moderate and 0.5-1.0 were considered strong 
(106). Significance level was set at p≤0.05. All data analysis was performed using the 
R software/environment. R is an open source project that is distributed under the GNU 
General Public License (Copyright 2007 Free Software Foundation, Inc) (107). 
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3.2. Part II: Novel application of the reversed gradient Diffusion Weighted MRI method 
for tumor response assessment in head and neck cancers (including the novel design 
of a Phantom Distortion Assessment). - Experience at Meixoeiro University Hospital of 
Vigo, Spain
3.2.1. Patients
All patients included in the ARTFIBio project  have stages T3 or T4 HNSCC. 
They are treated with IMRT and the prescribed dose to the local planning target volume 
varies between 66 Gy and 70 Gy. Before and three months after treatment, these studies 
are performed on these patients: MRI study (T1w, T2w, and DW-MRI) and 18F-FDG 
PET/CT study (101, 108). Two MRI examinations are conducted during the course of 
treatment: 
•	 During treatment: MRI study (T1w, T2w, and DW-MRI) at 2 time points.
o First time point :10 - 30 Gy [1-2 weeks during treatment]
o Second time point: 30 Gy – 60 Gy [3-4 weeks during treatment]
Three patients from the ARTFIBio project were selected to verify the improve-
ment in Mutual Information; data from one patient of the three were used to verify the 
improvement in the tumor assessment using the reversed gradient method.
3.2.2. Image acquisition protocols
All MRI examinations were performed on a Philips 1.5-T scanner (Achieva; Phil-
ips Healthcare; Netherlands) at Meixoeiro University Hospital of Vigo, Spain with the 
patient in supine position and with the same immobilization system as in treatment de-
livery (thermoplastic mask, head support), but adapted to MRI requirements. DW-MRI 
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with b=0, 600 and 1000 s/mm² were obtained with these parameters: TE/TR (ms) = 77-
100/5000; FOV (cm): 25X25; Matrix Size: 120x97 and slice thickness of 6 mm. A Flex-
L coil (Philips Sense Flex Medium) was placed over the neck and over the phantom-DA. 
A second set of DW-MRI data with the reversed direction of the phase was acquired by 
switching the ‘fat-shift direction’ in the Philips user interface. The radiotherapy immo-
bilization system contributed to the reduction of moving artifacts. After image acquisi-
tion, an ADC map was calculated using the standard software on the imaging console 
(Achieva; Philips Healthcare).
Table 3. DW-MRI scan parameters.
MRI (Philips 1.5T) DW-MRI 
Sequence SS-EPI
TR (ms) 5000
TE (ms) 77-100 
NEX  2
FOV (cm) 25 x 25
Slice thickness (mm) 6
b-values (s/mm2) 0, 600, 1000
Acquisition Matrix 120RL x 97AP
3.2.3. Reversed Gradient Diffusion Weighted MRI Method for tumor response as-
sessment in head and neck cancers
It has been shown that in general the addition of a spatially-varying static mag-
netic field inhomogeneity [B(x,y,z)] causes spatial distortion along the rth axis (109). The 
rth axis is the direction in which the strength of the effective magnetic field gradient that 
allows phase encoding is applied, and rth can be the x, y, or z axis. Spatial distortion in 
single slice EPI acquisitions may therefore be considered to occur only during the phase 
encoding direction. In this study, the x, y, and z axes are chosen to correspond to the fre-
quency encoding, phase encoding, and slice-selective axes, respectively. The reversed 
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gradient correction method  uses a second acquisition performed under exactly the same 
conditions, supposing that the spatial shifting of the signal will occur in the opposite 
direction along the y-axis (91). The spatially shifted signal from y appears in the first 
image at (the frequency encoding gradient is denoted by Gy) :
= + ( , , )     [4]
The spatially shifted signal from y appears in the second image at:
= − ( , , )     [5]
Then the corrected coordinate can be calculated combining Eqns.[4] and [5]:
= 1+ 2
2
    [6]
The corresponding pairs of y-values in the distorted MRI need to be located (92). 
Corresponding pairs can be found by performing line integrals of pixel intensity in dis-
torted MR images, i1 and i2, along each frequency encoding line. Corresponding values 
of y1 and y2 are identified as those that equalize the two integrals. However, correcting 
the spatial distortion alone does not yield a correct image, i. The Jacobian of the coordi-
nates transforms from distorted to undistorted space and is used to compensate for the 
effect of the transform on the pixel intensity. This method is extensively explained in 
Morgan et al. (92).
We corrected all distorted datasets (DW-MRI, b = 0, 600 and 1000 s /mm²) with 
the SPM8 software selecting the HySCO options to apply the reversed gradient method. 
The software can be freely downloaded from a webpage, where extensive documenta-
tion is available (110, 111). The standard settings of the method were used: dimension of 
phase encoding y (Antero-Posterior Direction), Maximal data resolution full; Smooth-
ing of Spline-Interpolation 0.1, Weight for “diffusion” regularizer 50; Weight for “Jaco-
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bian” regularizer 10. (110, 112). The movement associated with the increase of the scan 
time was reduced by the use of the immobilization systems also used in RT, during the 
acquisition.
The software exported the images in the nii format, which were converted to the 
Digital Imaging and Communications in Medicine (DICOM) format with an in-house 
tool, based on the Insight Segmentation and Registration Toolkit (ITK) libraries.
3.2.4. Novel Design of Phantom-Distortion Assessment
 A phantom called distortion assessment (DA) was developed for this study (Fig. 
13), specifically designed to assess the distortion in DW-MRI. It consists of a 17 x 17 x 
17 cm³ polyethylene HD 500 (PE-HD500) cube, which contains 10 rows by 5 columns 
of empty cylindrical hollows (diameter: 14 mm) in two sides. The design was built by 
SIHO Ltd (Vigo, Spain). Different cylindrical hollows of the phantom-DA were filled 
with water and were kept in the MRI room for 24 hours in order to reach room tempera-
ture. Before the study, the water temperature was measured. An MRI (T2w Turbo Spin 
Echo and DW-MRI) was performed on this phantom-DA to evaluate distortion.
Fig. 13. a. Phantom-DA, specifically designed for distortion assessment. b. CT Axial image of empty 
Phantom-DA, c. T2w MRI Axial image of Phantom-DA, Cylindrical hollows are filled with water.
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3.2.5. ARTFIBio software and calculations of mutual information
All datasets (CT-Scan, MRI studies, dose distribution) were registered using in-
house software ARTFIBio 0.6.2, in order to extract each voxel ‘s information. This soft-
ware includes a specific tool to calculate mutual information of two different sets of 
images. For the datasets from the same MRI study, no registration is needed, and only 
mutual information is calculated. The value of this metric was used to evaluate the grade 
of improvement in image distortion with and without the reversed gradient method; no 
additional non-rigid registration process was considered as the purpose of this study was 
primarily to evaluate the reversed gradient method. 
The simulation CT study was registered with the DW-MRI to associate the dose 
to each voxel. The registration process of the two datasets consisted of a two-step pro-
cess: 1) Manual registration: making a rough manual alignment (translation and/or rota-
tion) of the images (DW-MRI; CT-Scan; PET/CT) interactively on screen; 2) Automatic 
Rigid Registration: Once the images were approximately aligned, a more precise align-
ment (full rigid transformation) was performed based on an iterative process evaluated 
by statistical metrics (Mattes mutual information cost metric (102).
3.2.6. ADC calculations and tumor response evaluation
ADC was recalculated from undistorted images corrected by the reversed gradi-
ent method, and then the ADC variation during treatment was compared with delivered 
dose for corrected and raw images. The ADC was also recalculated from raw images to 
avoid discrepancies due to different ADC calculation methods.
According to Stejskal & Tanner’s work and considering the monoexponential 
approximation, the signal is attenuated according to (41, 103):
= · ·     [7]
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Where S1 is the signal value of the images at b-value, b-value varies between 
0, 600 and 1000 s / mm², and fitting the data to this equation, we can obtain the ADC 
values. 
For the patient, the signal intensity (SI) values were extracted from DW-MRI of 
the whole tumor volume using ARTFIBio-tool (101). The registration process described 
above was done with diffusion MRI for three different b-values.  For the phantom-DA, 
different ROIs were drawn in the water cylindrical hollows of the phantom-DA, using 
the tool ImageJ (113). The signal intensity (SI) values of the different ROI’s were ex-
tracted. The monoexponential approximation was used to fit the SI of the three b-values 
in order to obtain the corresponding ADC metric (103). In addition, the ADC value of 
water from raw images and corrected images was compared.
3.3. Part III: Intra Voxel Incoherent Motion Diffusion Weighted MRI and Dynamic Con-
trast Enhanced MRI methods for tumor response assessment in Brain Metastases 
– Experience at Memorial Sloan-Kettering Cancer Center, USA
3.3.1. Diffusion Weighted MRI Ice-Water Phantom
The ice-water phantom designed by Chenevert et al.  consists of a 50 ml polypropyl-
ene tube and 1000 ml polypropylene wide mouth jar (95). The 50 ml tube is filled with 
distilled water, capped and fixed to the bottom of the 1000 ml jar. In this DW-MRI study, 
a jar was filled with cubed ice and water and the phantom was cooled for approximately 
30 min prior to the scanning. After the initial cool-down period, more cubed ice was 
added to replace the melted ice.
The MRI series was performed on a Philips 3-Tesla MRI scanner (Ingenia; Philips 
Healthcare, Netherlands) and on a General Electric 3-Tesla MRI scanner (General Elec-
tric, Milwaukee, WI) at MSKCC with the phantom positioned in the head array coil 
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with the measurement tube axis along superior-inferior direction. DW-MRI with b=0, 
500, 800, 1000 and 2000 s/mm² were obtained with these parameters: TE/TR (ms) = 
77/8000; FOV (cm): 24x24; Acquisition Matrix Size: 128x128 and slice thickness of 5 
mm. A total of 4 DW-MRI were performed to study repeatability in immediate succes-
sion under controlled settings (Table 4). 
Table 4. DWI Icewater Phantom scan parameters.
MRI (GE 3T; Philips 3T) DW-MRI 
Sequence SS-EPI
TR (ms) 8000
TE (ms) 77 
NEX  2 
FOV (cm) 24 x 24 
Slice thickness (mm) 5 
b-values (s/mm2) 0, 500, 800, 1000, 2000 
Acquisition Matrix 128RL x 128AP
Reconstruction Matrix 256 x 256
3.3.2. Design of the study
All the patients involved in this study underwent the workflow shown in Fig. 
14. MRI exams were performed with the following timeline. Pre-treatment: MRI study 
(T1w, T2w, IVIM DW-MRI and DCE-MRI). Early post-treatment (within 1-72 hours): 
MRI study (T1w, T2w, IVIM DW-MRI and DCE-MRI). In addition, follow up MRI 
(with DW-MRI) at 2, 6 and 12 months was performed as part of standard clinical care 
at MSKCC.
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Fig. 14. Workflow representing the study design for all BM patients at MSKCC.
3.3.3. Patients
This prospective imaging study was approved by the Memorial Sloan-Kettering Can-
cer Center (MSKCC) institutional review board for patients with BM treated with SRS. 
The subject inclusion eligibility criteria required adults aged 18 and over, who are clinically 
stable and who do not require oxygen or cardiovascular monitoring, whose weight does 
not exceed 125 kg and who had metastatic brain tumors from any pathology greater than 
or equal to 1.0 cm that will be treated with SRS. After giving informed consent, 14 patients 
were enrolled in this prospective MRI study. Of these, 11 patients underwent SRS and 3 
were not treated ultimately treated. Of these 11, 9 completed pre- and early post-Tx MRI 
and 2 did not get the early post-Tx MRI. Thus, the final study population included 9 patients 
(5 males and 4 females), with a mean age (mean ± SD) of 61 ± 12 years old. The locations 
of primary tumors in patients were lung (4 patients), melanoma (2 patients), prostate (1 pa-
tient), rectum (1 patient) and HNSCC (1 patient). Patient characteristics are given in Table. 
5. For these 9 patients, the early post-Tx MRI was performed between 2 to 24 hours, keeping 
in accordance with the study design which needed early post-Tx to be within 1-72 hours.
The clinical follow-up was classified as NED, AWD, DOD and DOC (100). Loco-re-
gional and distant metastases control was assessed at approximately 3 months after comple-
tion of treatment. All patients had a clinical follow-up between 3-12 months.
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Table 5. Characteristics of the patients involved in this study.
Characteristics Value
Total patients 9
Demographics
Mean age (yr) 61
Age Range (yr) 47-80
Male/Female 5/4
Location of Primary tumor
Lung 4
Melanoma 2
Prostate 1
Rectum 1
HNSCC 1
Radiation Therapy technique SRS
Dose (Gy) 18-21
Fractions 1
Outcome
Alive with disease (AWD) 7
Dead of Disease (DOD) 1
No evidence of disease (NED) 0
Dead due to Other Cause (DOC) 1
3.3.4. Image acquisition protocols
A total of 18 MRI exams were performed on 9 BM patients who were treated with 
SRS. MRI examinations were performed on a Philips 3T MRI scanner (Ingenia; Philips 
Healthcare, Netherlands) using a neurovascular phased-array coil at MSKCC. The standard 
MR acquisition parameters were as follows: multiplanar (axial, coronal, and sagittal) T2-
weighted (T2
W
), fat-suppressed, fast spin-echo images TR= 4000 ms; TE = 80 ms; number of 
averages (NEX) = 2; matrix = 256 × 256; slice thickness= 5 mm, FOV= 20-24 cm and mul-
tiplanar T1w images (TR=600 ms; TE= 8 ms; NEX= 2; slice thickness= 5.0 mm; matrix= 
256 × 256, FOV = 20-24 cm. Standard T1w and T2w imaging was followed by DW-MRI.
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3.3.4.1. Intra Voxel Incoherent Motion Diffusion Weighted MRI
The IVIM DW-MRI data was acquired using a SSEPI sequence with 10 b-values 
(i.e., b=0, 20, 50, 80, 200, 300, 500, 800, 1500, 2000 s/mm2). Other MR parameters were 
as follows: TR = 4000 ms, TE = 98-104 ms, NEX = 2, matrix = 128 × 128, FOV = 24 
cm, slices = 8-10, slice thickness = 5 mm. 
3.3.4.2. Dynamic Contrast Enhanced MRI
A 3D-SPGR pulse sequence with 3 flip angles (FA=30o, 15o, 5o) was used for 
native T1 mapping, followed by dynamic imaging with contrast agent administration 
(FA=30o, TR = 4.6 ms, TE = 2.4 ms, phases = 40-60, NEX = 1, FOV: 24 cm, slice thick-
ness =5 mm.  The contrast agent Gd-DTPA was delivered by antecubital vein catheters 
at a bolus of 0.1mmol/kg and 2 cc/s, followed by saline flush.
Table 6. IVIM DW-MRI and DCE-MRI scan parameters.
MRI (Philips 3T) IVIM DW-MRI DW-MRI DCE-MRI* 
Sequence SS-EPI SS-EPI 3D-SPGR 
TR (ms) 4000 4.6 
TE (ms) 98-104 2.4 
NEX  2 1 
FOV (cm) 24 24 
Slice thickness (mm) 5 5 
b-values (s/mm2) 0, 20, 50, 80, 200, 300, 
500, 800, 1500, 2000 
0, 1000
Phases 40-60 
Flip Angle (deg) 30 
*Pulse sequence 3D-SPGR with 3 flip angles (FA=30o, 15o, 5o) was used for native T1 mapping.
  The contrast agent Gd-DTPA was delivered by antecubital vein catheters at a bolus of 0.1 mmol/kg and 2 cc/s.
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3.3.5. Image Analysis
3.3.5.1. Multi b-value Diffusion Weighted MRI Image Analysis
ROIs were delineated on the BM by an experienced neuro-radiologists on the 
DW-MRI image (b = 0 s/mm2). Before contouring the ROIs, the T2w/T1w images were 
used to determine localization and tumor extent.
The multi b-values DW-MR data were fitted to the models detailed below: 
Monoexponential model was used to calculate composite ADC with all the b-
values using Eqn. [7] (39),
The  bi-exponential IVIM model (42) (Eqn. [8]) is:
= 0 [
( − * )  + ( 1 − ) ( − ) ]    [8]
where S0 is the signal intensity without diffusion weighting, S represent the signal 
intensity with the diffusion weighting factor, b is the gradient factor (s/mm2), f is the 
microvascular perfusion volume fraction, D is the true diffusion coefficient (mm2/s), and 
D* is the pseudo-diffusion coefficient (mm2/s).
The metrics derived from IVIM DW-MRI were estimated using a nonlinear least-
square curve fitting method as detailed by Lu et al. (114, 115). A noise floor rectification 
scheme was optimized to generate IVIM metrics on a voxel-by-voxel basis (115). Fig. 
15 shows the IVIM fitting for the IVIM DW-MRI data acquired with multi b-value. All 
post-processing analyses were performed using in-house scripts written in MATLAB 
(Mathworks, Natick, USA).
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Fig. 15. Logarithm of the MR signal intensity decay averaged over all voxels within the brain metastasis 
of a patient as a function of the b-value. The blue circles represent the experimental data, and the solid 
red line is the IVIM model fit.
Finally, a relative percentage change (Δ) in IVIM estimated imaging metrics 
(ADC, D, f) between pre- and early post-Tx was calculated as follows: 
∆ ( %) =
( )
 100 [9]
Where X0 represents the pre-Tx metric value and Xp represents early post-Tx 
metric value.
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3.3.5.2. Dynamic Contrast Enhanced MRI image analysis
Quantitative DCE-MRI analysis of the tumor tissue time course data was per-
formed using the two-compartment Tofts model. The observable spoiled gradient echo 
signal with CR bolus injection is given by:
S( t) = S
( )
(θ) ( )
e  sin(θ)       [10]
where S(t) is the signal intensity at time t, θ is the flip angle, R1 (t) (R1=1/T1) is the time 
course of longitudinal relaxation rate in the voxel, R2
* (R2*=1/T*2) is the transverse relax-
ation rate, TR is the repetition time, TE is the echo time, S0 is a constant associated with 
the scanner gain and proton density. 
The observable R1 derived from Eqn. [10] is given by:
R ( t) =
( )
(θ)
( ) (θ)
(θ)
 
    
[11]
The water protons relaxation rate R1 (=1/T1) in intravascular space  can be ex-
pressed as (116):
=  +ℜ  ( 1 − )       [12]
where R10p is the precontrast blood plasmal relaxation rate constant, Cp is the blood 
plasma CA concentration ( i.e., called AIF) ,  is the blood plasma CA longitudinal relax-
ivity and  is the mean value of Hematocrit of the microvasculature which is about 0.45 
in large vessels (117).
The tissue water protons relaxation rate constant R1 and tissue concentration, Ct, 
are related as (45);
 =  +   ℜ    [13]
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Where R10 is the precontrast tissue water protons relaxation rate constant and ℜ 
is the CA longitudinal relaxivity, Ct is the total tissue concentration which is the amount 
of CA distributed in the intravascular space and extracellular space:
= ∫ ( ) +       [14]
The Eqn. [13] can be re-written as:
R ( t) = R + × ∫ C ( τ) e dτ + C  v   ℜ    [15]
where Ktrans - volume transfer constant, kep (=Ktrans/ve.): rate constant from extracellular 
to intravascular space (extra- to blood), Cp- plasma concentration of CA, vp- plasma vol-
ume fraction and ve is the extracellular volume fraction.
ROIs were delineated on the BM by an experienced neuro-radiologist on the 
pre- uptake DCE-MRI image. Before contouring the ROIs, the T2w/T1w images were 
used to determine localization and tumor extent. A simplified two compartment standard 
model (SM) was used to estimate the following metrics: Ktrans (volume transfer con-
stant), ve (extracellular volume fraction), vp (plasma volume fraction). Using in-house 
scripts written in MATLAB (Mathworks, Natick, USA) we fitted the DCE-MRI data 
extracted from ROIs to the Eqn. [15]. Fig. 16. represents a typical DCE-MRI data fitted 
as explained above. A population-based AIF extracted, as reported previously, was used 
(118). Fig. 17 shows the population-based AIF.
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Fig. 16. R1 time course including SM fit following a bolus injection of contrast agent. The SM shows a 
good fit to the dynamic data.
Fig. 17. Contrast concentration over time in the middle cerebral artery following bolus injection of con-
trast agent.
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Finally, a relative percentage change in DCE-MRI estimated imaging metrics 
(Ktrans, ve, vp) between pre- and early post-Tx was calculated as follows: 
∆ ( %) =
( )
 100      [16]
Where Y0 represents the pre-Tx metric value and Yp represents early post-Tx 
metric value.
3.3.5.3. Tumor volume calculation
For each patient, the total tumor volume was calculated as the product of the 
area of the ROI and the slice thickness based on T2w images using image-J software 
(113).
 ( ) = ( )   ( )      [17]
3.3.6. Statistical analysis
3.3.6.1. Diffusion Weighted MRI Ice-Water Phantom Study
Two MR scanners from different vendors but with the same field strength (3T) 
were analyzed. To assess the differences in ADC values between the 4 measurements 
(passes) performed within, across vendors and between different ROIs drawn, a Stu-
dent’s t-test was used. Significance level was set at p≤0.05. The within-subject coeffi-
cient of variation was calculated for the repeatability measurements as recommended by 
Raunig et al. (119). A one-sample t-test was performed to determine differences of ADC 
values from the literature value of 1.1 x 10-3 mm2/s at 0oC (120).
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3.3.6.2. Brain Metastases Patients Study
In the present study, the pre-Tx and early post-Tx ADC, D, D*, f, Ktrans, ve, vp and 
total tumor volumes were used for data analysis estimated from 18 MRI examinations 
performed on 9 BM patients to capture early treatment related changes. A Student’s t-
test was used to compare the parametric differences related to early treatment changes 
and a Pearson correlation analysis was performed to report the correlation and p-value 
of all the metrics mentioned above in the pre-Tx time point, prior to any treatment, al-
lowing analysis of the correlation between to imaging parameters without the potential 
confounding effects of treatment (121). Correlations were reported, under the same stan-
dard guidelines of Chapter I. Absolute correlation of <0.3 was considered weak, 0.3-0.5 
were considered moderate and 0.5-1.0 were considered strong. Significance level was 
set at p≤0.05 (106). All data analysis was performed using the R software/environment. 
R is an open source project that is distributed under the GNU General Public License 
(Copyright 2007 Free Software Foundation, Inc) (107).
Chapter IV
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Chapter IV: Results
4.1. Part I: ARTFIBio project: A novel framework for adaptive radiotherapy based on 
functional images - Experience at Meixoeiro University Hospital of Vigo, Spain
All 6 patients were untreated at the first time point of multimodality imaging and had 
biopsy-proven SCC, and were HPV-. Among the 6 patients, a total of 11 neck nodal metastases 
and 5 primary tumors were analyzed (3 patients had more than one node and 1 patient had an 
unknown primary tumor site). Patients were grouped as follows based on clinical outcome: 
NED=1, AWD=3, and DOD=2 (Table 1). A total of 34 multimodality imaging data (DW-MRI 
imaging studies (n=24) and 18F-FDG PET/CT (n=10)) were analyzed to capture CRT response. 
There was a significant strong negative correlation (=-0.67, p=0.01) between pre-Tx mean 
SUV and pre-Tx mean ADC for the 11 lymph nodes and 5 primary tumors (Fig. 18).
Fig. 18. Relationship between pre-treatment mean SUV and pre-treatment mean ADC showing a significant strong 
negative inverse correlation.
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For a single patient who was NED at last clinical follow-up, both MRI and 18F-FDG 
PET/CT post treatment showed no evidence of disease at primary tumor site and neck nodal 
metastases. Fig. 19 shows the DW-MRI and 18F-FDG PET/CT images from a patient who was 
NED. The ADC values (mean ± SD) for the ROIs drawn on primary tumor were 0.85 ± 0.27 x 
10-3 mm2/s, 1.49 ± 0.13 x 10-3 mm2/s for pre-Tx, Wk2-3 Tx respectively. The ADC values for the 
ROI in neck nodal metastases showed similar trends in the metric values and were as follows 
0.86 ± 0.20 x 10-3 mm2/s, 1.39 ± 0.08 x 10-3 mm2/s for pre-Tx, Wk2-3 Tx. pre-Tx SUV (mean 
± SD) values for primary tumor and neck nodal metastases were 5.99 ± 0.61 and 6.06 ± 0.49 
respectively.
Fig. 19. Representative NED patient. a. and g. pre-Tx PET/CT of the primary tumor and a neck nodal metastasis. 
b. and h. Primary tumor and representative neck nodal metastasis contoured over a T2W MRI. c. and i. pre-Tx 
ADC map overlaid on T2W MRI. d. and j. Wk2-Tx ADC map overlaid on T2W. e. and k. Wk3-Tx ADC map 
overlaid on T2W. f. and l. T2W MRI post-Tx with no evidence of primary tumor and neck nodal metastases.
Three patients were AWD on last clinical follow-up, and 1 patient had an unknown 
primary tumor site.  Both, MRI and 18F-FDG PET/CT post treatment showed no evidence of 
disease at primary tumor site but the neck nodal metastases were still present. Fig. 20 shows 
the DW-MRI and 18F-FDG PET/CT images from a patient who was AWD. The ADC (mean ± 
SD) for the primary tumors were 1.73 ± 0.09 x 10-3 mm2/s, 2.01 ± 0.36 x 10-3 mm2/s for pre-Tx, 
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Wk2-3 Tx respectively. The ADC values for the neck nodal metastases were 1.34 ± 0.22 x 10-3 
mm2/s, 1.47 ± 0.35 x 10-3 mm2/s, 1.93 ± 0.22 x 10-3 mm2/s for pre-Tx, Wk2-3 Tx, and post-Tx 
respectively. SUV mean pre-Tx value for Primary tumor and neck nodal metastases were 1.84 
± 0.83 and 4.85 ± 0.75 respectively.
Fig. 20. Representative AWD patient. a. and g. pre-Tx PET/CT of the primary tumor and two neck nodal me-
tastases. b. and h. Primary tumor and representative neck nodal metastasis contoured over a T2W MRI. c. and i. 
pre-Tx ADC map overlaid on T2W MRI. d. and j. Wk2-Tx ADC map overlaid on T2W. e. and k. Wk3-Tx ADC 
map overlaid on T2W. f. and l. T2W MRI post-Tx with no evidence of primary tumor but with presence of neck 
nodal metastasis.
The two patients who were DOD died, 2 months and 6 months after treatment. Fig. 21 
shows the DW-MRI and 18F-FDG PET/CT images from a patient who was DOD. The ADC val-
ues (mean ± SD) for the primary tumor were 1.51 ± 0.01 x 10-3 mm2/s, 1.83 ± 0.18 x 10-3 mm2/s 
for pre-Tx, and Wk2-3 Tx, respectively. The ADC values for the neck nodal metastases were 
1.39 ± 0.06 x 10-3 mm2/s, 1.61 ± 0.28 x 10-3 mm2/s, 0.98 ± 0.29 x 10-3 mm2/s for pre-Tx, Wk2-3 
Tx, and post-Tx respectively. SUV mean pre-Tx value for primary tumor and neck nodal metas-
tases were 2.98 ± 0.66 and 3.93 ± 0.45 respectively. A summary of data from the three different 
survival groups as DOD, AWD and NED is shown in Table 2.
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Fig. 21. Representative DOD patient. a. and g. pre-Tx PET/CT of the primary tumor and three neck nodal me-
tastases. b. and h. Primary tumor and representative neck nodal metastasis contoured over a T2W MRI. c. and i. 
pre-Tx ADC map overlaid on T2W MRI. d. and j. Wk2-Tx ADC map overlaid on T2W. e. and k. Wk3-Tx ADC 
map overlaid on T2W. f. and l. T2W MRI post-Tx with no evidence of primary tumor but with presence of neck 
nodal metastasis.
Fig. 22 and 23 show different trends for the three survival groups DOD, AWD and NED 
by representative patients. The results depicted in individual patients are the relative percentage 
(%) change in ∆ADC for primary tumors and neck nodal metastases. The results between Pre- 
and Wk2 Tx for primary tumor and neck nodal metastases in a patient with NED were 86.55% 
and 68.60% while for AWD and DOD they were 18.51%, 11.88%  and 29.76%, 25.77%, re-
spectively. The percentage (%) change in ∆ADC for primary tumors and neck nodal metastases 
between Pre- and Wk3 Tx  for patients with NED was 64.26%, 54.65% while for AWD and 
DOD it was 36.48% , 53.58%, and 24.13%, -11.14%, respectively. A summary of data from the 
three different survival groups as DOD, AWD and NED is shown in Table 2.
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Fig. 22.  ADC Pre- and intra-Tx (2nd and 3rd week) versus week of treatment in primary tumors of HPV – HNSCC 
patients who were classified based on survival as DOD, AWD and NED.
Fig. 23. ADC pre- and intra-Tx (2nd and 3rd week) versus week of treatment in neck nodal metastases HPV – HN-
SCC patients who were classified based on survival as DOD, AWD and NED.
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Table.7 ADC metric values for HPV– HNSCC patients who were classified based on survival as DOD, AWD and 
NED before and during and post CRT.
MRI
DOD
ADCmean(10
-3 mm2/s)
AWD
ADCmean(10
-3 mm2/s)
NED
ADCmean(10
-3 mm2/s)
Primary Node Primary Node Primary Node
pre-Tx 1.51±0.36 1.43±0.58 1.66±0.41 1.26±0.19 0.86±0.20 0.85±0.27 
During-Tx 
(2-3 weeks) 
1.92±0.33 1.54±0.11 2.12±0.38 1..41±0.38 1.39±0.47 1.50±0.44 
Post-Tx No Primary 0.98±0.29 No Primary 1.93±0.22 No Primary No Node 
Fig. 24 and 25 show Pre- and Wk3-Tx ADC in representative patients from three clinical 
follow-up groups DOD, NED and AWD.  The histograms display the changes in diffusion for 
primary tumor and neck nodal metastases.
Fig. 24. Histogram plots depicting changes in the distribution from Pre- to Wk-3 during Tx for ADC (x 10-3 mm2/s) in 
primary tumors of HNSCC patients. Three clinical follow-up groups represented are DOD, NED and AWD.
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Fig. 25. Histogram plots depicting changes in the distribution from Pre- to Wk-3 during treatment for ADC (x 10-3 
mm2/s) in neck nodal metastases of HNSCC patients. Three clinical follow-up groups represented are DOD, NED 
and AWD.
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4.2. Part II: Novel application of the reversed gradient Diffusion Weighted MRI method for tu-
mor response assessment in head and neck cancers (including the novel design of a Phan-
tom Distortion Assessment - Experience at Meixoeiro University Hospital of Vigo, Spain
Fig. 26 shows original images of the phantom-DA and one of the patients. In addition, 
two distorted images with opposite phase encoding directions and its corresponding corrected 
image are represented. The visual improvement in the registration was notable, and in patient’s 
sagittal slices we see that the registration of the cord and the brain of the corrected images fit 
much better to the real anatomic position on the CT. 
Fig. 26. The upper figure shows the DW-MRI with b=0 for the Phantom-DA: a. Phase encoding direction: Antero-
Posterior, fat shift anterior (AP); b. Phase encoding direction: Antero-Posterior, fat shift posterior (PA); c. Cor-
rected by the reversed gradient method. The lower figure shows the registration of CT and DW-MRI with b=0 
for a patient:  d. Phase encoding direction: Antero-Posterior, fat shift anterior (AP); e. Phase encoding direction: 
Antero-Posterior, fat shift posterior (PA); f. Corrected by the reversed gradient method.
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As distortion is the main disadvantage of using DW-MRI for tumor response assess-
ing, correction will be validated by the reversed gradient method in order to show the im-
provement in image registration and accurate ADC measurements. Mutual information will 
be used for the numerical quantification of distortion. The DW-MRI images with different 
b-values were used, considering distorted and undistorted images corrected by the reversed 
gradient method. They were registered with the T2w study. As perfect registration, two iden-
tical T2w images of the phantom-DA were chosen, and the mutual information value ob-
tained was 1.33426.
Table 8 displays the different mutual information values and difference for the registra-
tion of the images with T2w, with and without correction. An average improvement of 23% in 
mutual information was obtained.
Table 8. Mutual Information values for the registration of T2w MRI and DW-MRI with different b-values of the 
phantom-DA. % difference is calculated with respect to averaged mutual information of raw studies, considering 
both gradients. Raw AP and raw PA correspond to the reversed gradients applied for phase encoding direction in 
the AP dimension and different fat shifts.
Phantom-DA Raw AP Raw PA Corrected % Difference
b=0 s/mm2 0.420 0.461 0.499 13.21%
b=600 s/mm2 0.482 0.403 0.543 22.73%
b=1000 s/mm2 0.453 0.377 0.563 35.59%
The patient’s datasets were processed by calculating the upper value of mutual in-
formation in the registration of the T2w MRI of the patient with itself and obtained a value 
of 1.853.
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Table 9 shows different mutual information values for the registration of the MRI im-
ages, with and without distortion correction, with T2w for each dose point. An average registra-
tion improvement of 21% was obtained.
Table 9. - Mutual information values for different DW-MRI of the three patients with different b-values and T2w 
MRI. % difference is calculated with respect to averaged mutual information of raw studies, considering both 
gradients. Raw AP and raw PA correspond to reversed gradients applied for phase encoding direction in the AP 
dimension and different fat shifts.
Patient b-value ( s/mm2) Raw AP Raw PA Corrected % Difference
#1 0 0.563 0.656 0.872 43.1 %
#2 0 0.308 0.454 0.775 103 %
#3 0 0.439 0.548 0.548 11.0 %
#1 600 0.655 0.325 0.900 83.7 %
#2 600 0.381 0.445 0.730 76.8 %
#3 600 0.545 0.522 0.567 6.28 %
The ADC value of water in the phantom-DA was calculated. The ADC value obtained 
for water at 22º C is (2.13 ± 0.19) × 10-3 mm² / s for distorted images and (2.19 ± 0.05) × 10-3 
mm² / s for undistorted images. Differences in both values were not significant and they cor-
respond to published data (122): 2.13 × 10-3 mm² / s.
Tumor response was evaluated by measuring the difference in ADC values during treat-
ment for raw and corrected datasets in one of the three patients (84, 123). Fig. 28 shows the 
ADC change voxel by voxel for both datasets. A closer cluster in ADC can be seen, as expected 
of the corrected dataset, and observations of the average data (Fig. 28) indicate that the ADC 
increment in the 16th fraction is only noticed for corrected data, probably because distortion 
adds noise to the original signal and the correlation of the ADC increment with dose is lost. 
Accurate ADC measurements can be made using the corrected method, which is critical for an 
imaging biomarker of response.
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Fig. 27. ΔADC (10-3 mm2/s) vs Dose (Gy) in the tumor. Each point represents the voxel ΔADC values extracted 
from a. DW-MRI RAW, b. DW-MRI corrected at the 12th and 16th fractions of Treatment.
Fig. 28. Dose course of ADC (10-3 mm2/s) in the tumor of a patient at the 12th and 16th fractions of Treatment.
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4.3. Part III Intra Voxel Incoherent Motion Diffusion Weighted MRI and Dynamic Con-
trast Enhanced MRI methods for tumor response assessment in Brain Metastases 
– Experience at Memorial Sloan-Kettering Cancer Center, USA
4.3.1. Repeatability and reproducibility of Quantitative Imaging Biomarkers: Dif-
fusion Weighted MRI as a test model
ADC metric value for distilled water at 0oC is 1.1 x 10-3 mm2/s (124). The phan-
tom required 30 minutes to reach an equilibrium temperature of 0oC (Fig. 29). The dif-
fusion metric values of water show a high sensitivity to temperature (2.4% change in 
value per degree Celsius) (120). Hence, it is a prerequisite to have a stable temperature 
over the scan time.
Fig. 29. a. Illustrates the phantom filled with ice. b. Sagittal representative T2w image of the phantom. c. 
Axial representative b=0 s/mm2 image of the phantom. d. Axial ADC map of the phantom. Note: Red box 
denoted the ROI used for ADC measurement.
This study showed that ADC measurements of the ice-water phantom at the ROI 
(d.) were consistent with the literature value of 1.1 x 10-3 mm2/s at 0oC (120). In Fig.30 
are the grouped ADC values, acquired at b-values of 0, 500, 800, 1000 and 2000 s/mm2, 
from the ice-water phantom for each scanner, Philips-3T and GE-3T. A total of 24 mea-
surements were obtained within a 5% (blue field in Fig. 30) of the literature value of 1.1 x 
10-3 mm2/s (orange line in Fig. 30). The mean value of ADC for the GE-3T was (mean ± 
SD) 1.09 ± 0.01 x 10-3 mm2/s and for GE-1.5T was (mean ± SD) 1.11 ± 0.02 x 10-3 mm2/s. 
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Fig. 30. Measurements of ADC in the ice-water phantom for 4 passes and three different ROIs, separated 
by vendor.
ADC values acquired at Philips-3T and GE-3T showed no statistical difference 
between the 4 measurements (passes) performed within and across vendors and between 
different ROIs drawn. The coefficient of variation of the repeatability measurements for 
GE-1.5T was 1.2%. Meanwhile, the coefficient of variation of the repeatability mea-
surements for GE-3T was 0.9%. Therefore, they indicate that the ADC measured for the 
phantom is repeatable and reproducible.
4.3.2. Intra Voxel Incoherent Motion Diffusion Weighted MRI and Dynamic Con-
trast Enhanced MRI methods for tumor response assessment in Brain Me-
tastases
The final analysis was performed on the 9 BM patients. Patients were grouped as 
follows based on clinical outcome: NED=0, AWD=7, DOD=1 and DOC = 1 (Table 6). 
A total of 39 DW-MRI (pre-, early post-Tx and follow up) and 18 DCE-MRI (pre- and 
early post-Tx) imaging studies were analyzed to capture early SRS treatment response.
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There is a significance strong positive correlation between mean ADC and mean 
D (=0.987). There is a moderate negative correlation between mean D and mean f 
and Ktrans values (=-0.320, =-0.330, respectively).  A significance strong positive cor-
relation is also shown between mean f and mean vp and Ktrans values (=0.742, =725, 
respectively). In addition, a significance strong positive correlation between mean Ktrans 
and mean ve value was found (=0.547) and a moderate positive correlation between 
mean Ktrans and mean vp (=0.380) for BM patients with AWD. All Pearson correlation 
coefficients are listed in Table 10 for BM patients who were AWD. Statistical analysis 
for correlations was not performed for patients who were DOD and DOC to avoid pa-
tient bias due to low sample size. 
Table 10. Summary statistics of Pearson correlation between all imaging metrics derived 
from IVIM DW-MRI and DCE-MRI for BM patients who were AWD. Note: Asterisks (*) 
showing sig   nificance between all imaging metrics.
Pearson Correlation AWD (*p-value ≤ 0.05)
Metrics D f Ktrans ve vp
ADC ρ=0.987* ρ=-0.200 ρ=-0.260 ρ=-0.001 ρ=-0.106
D ρ=-0.320 ρ=-0.330 ρ=-0.036 ρ=-0.015
f ρ=0.725* ρ=0.209 ρ=0.724*
Ktrans ρ=0.547* ρ=0.380
ve ρ=-0.005
Absolute correlation considered 
Strong 0.5<ρ≤1, Moderate 0.3≤ρ≤0.5, Weak ρ<0.3
The relative percentage change in the IVIM metrics (∆ADC, ∆D and ∆f) and 
DCE-MRI SM metrics (∆Ktrans, ∆ve, ∆vp) between pre- and early post-Tx (2-24 hours) 
for the BM patient who DOD was -8.00%, -9.28%, -4.26%, -25%, -21.65%, 196%. The 
relative percentage change in the IVIM metrics (∆ADC, ∆D and ∆f) and DCE-MRI SM 
metrics (∆Ktrans, ∆ve, ∆vp) between pre- and early post-Tx (2-24 hours) for the BM pa-
tient who DOC was 12.32%, 19.5%, 3.99%, -29.59%, -29.42%, 128%.  
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Fig. 31 and 32 show the pre- and early post-Tx IVIM and DCE-MRI SM metric 
maps from a representative BM patient.
Fig. 31. Brain Metastasis patient depicting the early changes in IVIM metrics pre- and early post-Tx.  a. 
A brain metastasis contoured on a T2w MRI. b.-e. pre-Tx ADC, D, f, D* maps. f.-i. Early post-Tx ADC, 
D, f, D* maps. All maps are overlaid on T2w MRI.
Fig. 32. Representative Brain Metastasis patient depicting the early changes in DCE metrics pre- and early 
post-Tx. a. Brain metastasis contoured on a T1w MRI. b.-e. pre-Tx Ktrans, ve, vp  maps. f.-i. Early post-Tx 
Ktrans, ve, vp maps. All maps overlaid on T1w MRI.
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Seven patients were AWD on last clinical follow-up. The pre-Tx ADC, D and f 
(mean ± SD) were 0.89 ± 0.33 x 10-3 mm2/s, 0.69 ± 0.33 x 10-3 mm2/s, and 0.27 ± 0.09 
respectively. The pre-Tx Ktrans, ve and vp (mean ± SD) values were 0.19 ± 0.09 min-1, 0.20 
± 0.09, and 0.01 ± 0.01, respectively. The early post-Tx ADC, D and f (mean ± SD) were 
1.03 ± 0.48 x 10-3 mm2/s, 0.85 ± 0.54 x 10-3 mm2/s, and 0.25 ± 0.10 respectively. The 
early post-Tx Ktrans, ve and vp (mean ± SD) values were 0.17 ± 0.06 min-1, 0.28 ± 0.23, 
and 0.01 ± 0.01, respectively. 
The relative percentage changes in the IVIM metrics (∆ADC, ∆D and ∆f) and 
DCE-MRI SM metrics (∆Ktrans, ∆ve, ∆vp) between pre- and early post-Tx (2-24 hours) for 
the AWD group of patients were 15.43%, 23.64%, -8.05%, -10.95%, 41.35%, -44.39%. 
A summary of data from the group of AWD is shown in Table 11. In Fig. 33 are  pre- and 
early post-Tx values for ADC, D and Ktrans in a representative patient. The histograms 
display the changes in diffusion and vascular permeability in BM patients who were 
AWD.
Table 11: Relative percentage change ∆ADC, ∆D, ∆f, ∆Ktrans, ∆ve, ∆vp, pre- and post-SRS (2-24 hours), 
values for BM patients who were classified based on survival as AWD. 
ΔADC 
(2-24 hours) 
ΔD 
(2-24 hours) 
Δf 
(2-24 hours) 
ΔK
trans 
(2-24 hours) 
Δv
e
 
(2-24 hours)
Δv
p
 
(2-24 hours)
15.43 % 23.64 % - 8.05 % - 10.95 % 41.35 % - 44.39 % 
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Fig. 33. Corresponding distribution histograms plots for the metrics, ADC (x 10-3 mm2/s), D (x 10-3 mm2/s) 
and Ktrans (min-1) of a representative BM patient.
Fig. 34 and 35 illustrate ADC and tumor volume changes during long term fol-
low up for three representative patients.
Fig. 34. Time course trend of ADC at differ time points (pre-, post (2-24 hours, 2 month, 6 month, 12 
months) for three representative BM patients.
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Fig. 35. Time course trend of tumor volume at differ time points (pre-, post (2-24 hours, 2 month, 6 
month, 12 months) for three representative BM patients.
Statistical tests were not performed to compare the 3 group (AWD, DOD and 
DOC) in order to avoid patient bias due to low sample size in the study [see Table 5]. 
This study is showing for the first time that relative percentage changes occur in the 
imaging metrics in BM patients early within 2-24 hours post SRS. In BM patients who 
were AWD, there is a substantial change in imaging metric values for both DCE-MRI 
and IVIM DW-MRI pre- and early post-Tx.  A preliminary, initial Student t-test showed 
that when the patients in the AWD were compared based on the primary tumor site (for 
example 4 patients with lung primary tumor versus 2 patients with melanoma primary 
tumor [see Table 5]) the mean value of metric vp was significantly different (p<0.03) 
for early post-Tx.  Once again, it is important to clarify that in-depth statistical analysis 
was not in the scope of this study. This is a feasibility study showing trends observed in 
these BM patients being treated with SRS. It therefore constitutes a building block for 
future studies in clinical settings that will use functional imaging in adaptive RT settings.
Chapter V

–  81 –
Chapter V: Discussion
Chapter V of this thesis discusses in depth the three studies which have in common the 
central theme and motivation of using functional imaging in RT settings for future application 
in adaptive RT.
The first part of the discussion is focused on a prospective study of HPV- HNSCC pa-
tients analyzing 18F-FDG, pre- and post-Tx, and DW-MRI pre- during and post-Tx in primary 
tumors and neck nodal metastases, integrating them into the RT setting.
The second part of the discussion is focused on the accurate measurement of ADC de-
rived from DW-MRI, through the correction of geometrical distortion in DW-MRI using the 
reversed gradient method in HPV- HNSCC patients who underwent RT.
The last part of the discussion is divided into two subparts. The first focuses on repeat-
ability and reproducibility of ADC measurements derived from DW-MRI using a temperature-
controlled fluid phantom constructed by Chenevert et al. (95). The second focuses on a pro-
spective study of BM treated with SRS assessing early (1-72 hours post-Tx) treatment response 
evaluating imaging metrics derived from IVIM DW- and DCE- MRI.
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5.1. Part I: ARTFIBio project: A novel framework for adaptive radiotherapy based on 
functional images - Experience at Meixoeiro University Hospital of Vigo, Spain
HNSCC is one of the major types of cancer that can be linked to alcohol consumption 
and tobacco smoking; it typically originates from the mucosal epithelia of the oral cavity, phar-
ynx and larynx (125). Locoregional control can be achieved through treatment with radiation 
or surgery at the early stages, but only 40% of patients with advanced stages will survive more 
than 5 years (125). Regardless of recent advances in surgical and oncologic treatments, the 
overall survival rate of patients with HNSCC has unfortunately not improved much in recent 
years. Delays in diagnosis (followed by locoregional failure) and a late salvage treatment at the 
recurrence of the disease are important causes of unfavorable outcomes in this type of cancer. 
A priori predictors of outcome and predictive biomarkers of treatment response are desperately 
needed to advance patient care and individualized treatment.
In recent years, studies have shown the use of multimodality imaging (18F-FDG PET/CT, 
DW-MRI, DCE-MRI) in HNSCC assessing both the association between the QIBs obtained 
from each imaging technique and their combined or respective roles in prognosis and/or predic-
tion of outcome (10, 126-128). In this study for HPV- HNSCC patients, ADC as an established 
biomarker of treatment response was calculated by using DW-MRI. Non-linear mono-exponen-
tial fitting with three b-values was performed to estimate this metric. 18F-FDG PET/CT also has 
a growing evidence base supporting its importance in therapy assessment; the well established 
SUV, which measures the glucose metabolic uptake, was obtained in HPV- HNSCC patients.
As mentioned in the introduction of this thesis, major technical challenges in IMRT 
persist in the use of functional images for RT, one of which includes the identification of a 
reproducible, radiotherapy-compatible patient position that is consistent between functional 
techniques and RT.  All patients in the present study were in a supine position and fixed in place 
with the same immobilization system which was also used during the RT treatment planning 
and delivery. A thermoplastic mask, head support and flat table were used to try to minimize 
the distortion and to improve the registration process between the different imaging modalities. 
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The head support and flat table were adapted to MRI and PET/CT. This reproducible position-
ing addressed one of the big hurdles in the acquisition of multimodality images that may in the 
future be used for adaptive RT (85, 129). 
Dirix et al. designed a prospective multimodality imaging study with this prerequisite 
in mind, recruiting 17 patients with primary HNSCC and performing 18F-FDG, 18F-FMISO, 
DW-MRI and DCE-MRI pre-, during, and post-Tx while taking into account the importance 
of patient positioning under which RT would take place for adaptive RT purposes. This study 
concluded that 18F-FDG and 18F-FMISO are valuable additions for treatment planning purposes 
and suggests the potential of DW-MRI and DCE-MRI for dose painting and response assess-
ment (130). The INSIGHT study conducted by Welsh et al. and a study by Subesinghe et al. 
emphasized the importance of reproducing the positioning of  patients using the same neck rest, 
shoulder rest and thermoplastic mask under which RT treatment planning and delivery would 
take place (131, 132).
This prospective study is the first in Spain, conducted from the point of view of advocat-
ing for the integration of functional imaging in RT treatment, which recruits a specific popula-
tion of patients, HPV- HNSCC, analyzing 18F-FDG, pre- and post-Tx, and DW-MRI pre- during 
and post-Tx in primary tumors and neck nodal metastases.
Previous studies have established that in HNSCC patients glucose metabolic uptake 
from 18F-FDG is an effective tool for staging and therapy response assessment (58), and plays 
a fundamental role in adaptive RT (58, 133, 134). It is well known that ADC derived from 
DW-MRI is negatively correlated with tumor cell density (135), and furthermore is a useful 
biomarker to assess treatment response (11, 56). These two imaging techniques have been the 
focus of numerous studies in HNSCC to determine correlation, if any, between SUV and ADC 
values, with variable results. A study by Varoquax et al. involving 24 primary and 10 recurrent 
HNSCC tumors showed no significant correlation between SUV values (SUVmax, SUVmean or 
SUVmin) and ADC values (ADCmax, ADCmean or ADCmin), nor did Choi et al. find significance 
correlation between SUVmean and ADCmean in 47 primary HNSCC tumors (136, 137). Rather, 
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Nakajo et al. found significant negative correlation between SUVmax and ADCmean in a study of 
28 primary HNSCC tumors, and Nakamatsu et al. demonstrated significant negative correla-
tion in 41 neck nodal metastases between SUV values (SUVmax, SUVmean) and ADC values 
(ADCmean, ADCmin) (138, 139). In the present study, a total of 11 neck nodal metastases and 5 
primary HPV- HNSCC tumors showed a significant strong negative correlation, ADCmean and 
SUVmean pre-Tx (=-0.67, p=0.01). 
These discrepancies between studies can be related to non-standardized acquisition pa-
rameters. Another reason for this variability could be the variations among cohorts of patients. 
Preda et al. conclude in a study with 57 HNSCC primary tumors that “the combination of SU-
Vmax and ADCmin improves the prognostic role of the two separate parameters” (140). The mul-
timodal use of SUV and ADC have allowed this study to depict complex interactions between 
glucose metabolism and cellular density, making these biomarkers essential tools for adaptive 
RT purposes
IMRT has the ability to deliver a high dose to the tumor while minimizing side effects 
to surrounding healthy tissues (74). The high radiation dose delivered to the tumor induces a 
decrease in tumor cells, thus reducing restrictions on the mobility of water molecules at a mi-
croscopic level. Several studies have confirmed this “increased diffusion effect” as a marker of 
response to RT in HNSCC. 
Vandecaveye et al. reported that ΔADC (3 weeks after CRT) for primary tumors with 
complete remission were significantly higher than for recurrent lesions (56). Again, Vandecav-
eye et al. showed in neck nodal metastases and primary tumors that ΔADC (2 Week and 4 Week 
during CRT) was significantly lower in lesions with recurrence than in lesions with a complete 
response (141). 
The present study showed an increase in ΔADC
2Week
 for the patient with NED in com-
parison to the DOD and AWD patients in both primary tumor and neck nodal metastases, in 
agreement with above-mentioned studies. Also, the pre-Tx ADC value of the primary tumor 
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and neck nodal metastases for NED is lower than in the group of AWD and DOD, showing that 
lower pre-Tx ADC values are related to a good response to treatment and consistent with the 
literature (11, 142). ADC histograms showed microstructural heterogeneity in primary tumor 
and neck nodal metastases in the three groups (NED, AWD and DOD), as described in previous 
reports (143). The post-Tx ADC distribution curve illustrates the movement of water molecules 
in the extracellular space compared to pre-Tx. In the NED patient, a shift to higher ADC values 
for both primary tumor and neck nodal metastases reflects the improved pathologic response 
to RT. Furthermore, a wider range and higher pre-Tx ADC distribution can be seen in both 
primary tumor and neck nodal metastases for DOD and AWD patients, in comparison with the 
NED patient.
The ADC relative percent change trends shown for primary tumor and neck nodal me-
tastases depict the different responses to treatment, suggesting the possibility of identifying at 
an early stage patients with a good or bad prognosis to individualize and adapt RT treatment 
(i.e. through dose-escalation or dose de-escalation).
Recent studies suggest that Wk-2 and Wk-3 of treatment are promising time points to 
identify different outcomes, although the appropriateness of using these time points to establish 
an accurate measurement of outcome needs to be validated in larger populations (144). This 
individualization of treatment is especially important in the subgroup of HPV- patients that was 
studied as a part of this thesis. Given that the outcomes for HPV tumors differ, HPV- patients 
have worse outcomes compared to HPV+ counterparts (145).
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5.2. Part II: Novel application of the reversed gradient Diffusion Weighted MRI method 
for tumor response assessment in head and neck cancers (including the novel design 
of a Phantom Distortion Assessment) - Experience at Meixoeiro University Hospital of 
Vigo, Spain
In recent years, several approaches based on functional imaging have been proposed to 
predict tumor response, and many have been adapted for RT treatment. The main imaging tech-
niques used so far are PET/CT (25, 146, 147), MRI (15, 148) or a combination of both (108, 149). 
In MRI, DW-MRI has shown promise in monitoring response to CRT in HNC (9, 123, 150). 
For accurate measurement of ADC derived from DW-MRI, distortion must be mini-
mized. In clinical practice, DW-MRI images often have lower image quality compared to other 
conventional MR images like T1w/T2w due to image quality issues such as distortion, noise, 
low resolution and the presence of artifacts, most of which arise due to the usage of faster im-
age acquisition techniques such as EPI, essential for capturing the diffusion signal before it be-
comes null (16, 151). Because of its inherently low bandwidth per point in the phase encoding 
direction, EPI techniques exhibit more geometric distortion than spin warp MRI techniques. 
This problem must be addressed before assessing tumor response with DW-MRI and trying a 
voxel-wise analysis, because of the need to register the MRI images obtained during the treat-
ment with planning CT scans, dose distributions, or PET/CT scans. Fortunately, the geometric 
distortion can be reduced by using the reversed gradient method (91, 92) and other artifacts (like 
eddy currents) can be corrected by a serial of different b-values and simultaneous image seg-
mentation and iterative registration (152). There is also an interesting alternative to the reversed 
gradient method called the “phase labeling for additional coordinate encoding” (PLACE) tech-
nique (153). This method consists of a slightly modified additional EPI acquisition; they sample 
the k-t space with a shift in ky by adding a small area to the phase-encoding gradient.  As distor-
tion is the main disadvantage of using DW-MRI for tumor response assessment, the reversed 
gradient method was used for the purposes of this thesis to reduce geometric distortion and 
improve accuracy of ADC derived from DW-MRI.
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The reversed gradient method has not been used in previous studies that show ADC 
variation with radiation dose (15, 108, 148). Geometric accuracy is crucial when using func-
tional imaging in RT. The DW-MRI images corrected by the reversed gradient method also 
point out the feasibility of the voxel-wise approach to tumor response assessment using ADC 
and establish its clinical utility as an imaging biomarker of response.
Several phantoms have been developed for DW-MRI assessment but they are more fo-
cused on verifying ADC values than on evaluating distortion (154, 155). In the present study, a 
new phantom was specifically designed to evaluate geometrical distortion. The reversed gradi-
ent method was applied to both phantom images and DW-MRI images obtained from a patient 
included in the ARTFIBio project (108). The DW-MRI images were registered to T2w images 
of the phantom and the patient. The evaluation for mutual information on DW-MRI images 
was done with and without the reversed gradient method. The mutual information was used as 
a measure of goodness for the distortion correction. This is a widely used metric to evaluate a 
registration method for images obtained from different modalities (102). The reversed gradient 
method does not modify the calculated ADC value in the phantom while it helps to provide ac-
curate ADC measurement in tumors as a result of better registration during RT. 
This study is the first in Spain to be conducted from the point of view of advocating for 
an accurate measurement of ADC derived from DW-MRI in HPV- HNSCC patients, relying on 
the correction of geometrical distortion in DW-MRI using the reversed gradient method.
The visual improvement in the registration with the reversed gradient method applied 
was observed to show a better fit to the real anatomic position indicated in the CT. The numeri-
cal quantification of distortion calculated through the mutual information metric in undistorted 
DW-MRI images for both phantom and patients with different b-values, showed an improve-
ment in the mutual information metric with respect to distorted images. 
The values of ADC obtained after the correction agreed with the original values for 
the same volume. Considering this and the visual improvement in the registration process, the 
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reduced distortion obtained through mutual metric information, and the accurate measure of 
ADC,  correcting the distortion with the reversed gradient method is suggested before imple-
menting an imaging method of treatment response that uses ADC maps for assessing tumor 
response or tumor cell density variation.
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5.3. Part III: Intra Voxel Incoherent Motion Diffusion Weighted MRI and Dynamic Con-
trast Enhanced MRI methods for tumor response assessment in Brain Metastases 
- Experience at Memorial Sloan-Kettering Cancer Center, USA
This part of the discussion is divided into two sections framed as an experience at Me-
morial Sloan-Kettering Cancer Center (MSKCC) in the USA. The first section is related to the 
role of the Phantom study as a key part in the use of QIB. The second section is related to the 
evaluation of whether quantitative imaging metrics derived from IVIM DW- and DCE- MRI 
can assess early (1-72 hours post-Tx) treatment response in patients with BM treated with SRS.
5.3.1. Repeatability and Reproducibility of Quantitative Imaging Biomarkers: 
Diffusion Weighted MRI as a test model
For QIBs to be used in adaptative RT, it is a prerequisite to perform exhaustive 
phantom studies detailing the repeatability and reproducibility of the functional imag-
ing technique. This study plays a key part in the use of QIB at MSKCC from the point 
of view of advocating for standardizing data acquisition conditions across vendors and 
using a temperature-controlled fluid phantom with a specific procedure to minimize the 
bias in ADC measurements in DWI studies, assessing repeatability and reproducibility.
The RT process is complex and involves many areas of knowledge. Among them, 
radiation treatment planning and dosimetry needs quality control and quality assurance 
(QA) to avoid errors and to give high confidence that patients will receive the prescribed 
treatment correctly. In addition, clinical trial QA plays a significant role in enhancing 
the quality of care. 
To implement functional imaging in adaptive RT, the measurements obtained 
from the clinical situation being investigated must be in the range of the fluctuations 
of repeatability tests. The coefficient of variation is often used in repeatability studies 
to assess these fluctuations. In addition, maximization of tumor visualization and char-
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acterization is required. Both DW-MRI and the ADC maps should be evaluated with 
corresponding morphologic images. The suppression of background normal tissue sig-
nals, however, is desirable. This suppression of background signals can be achieved by 
performing DW-MRI with sufficient degrees of diffusion weighted. The signal intensity 
in b-value DW-MRI images generally obtained from tumor yields low ADC. In contrast, 
cystic or necrotic tissues show greater signal attenuation on high b-value images and 
have high ADC values, exhibiting the same behavior as some normal and pathologic 
tissues. The customization of DW-MRI protocols specific to different tumor types, tu-
mor locations, anatomic region, tissue composition, and pathologic processes need to 
be established for multimodality imaging studies which will use functional imaging for 
adaptive RT.
ADC values acquired for the phantom from different vendors showed no statisti-
cal difference between the 4 measurements performed within and across vendors and 
between different ROIs drawn. In addition a low coefficient of variation of the repeat-
ability measurements for each vendor was shown in the study. 
This study assessed the repeatability, reproducibility and quantitative quality 
control of ADC measurements across vendors of the same field strength using a stan-
dardized acquisition protocol. Using a temperature-controlled fluid phantom constructed 
by Chenevert et al., a specific procedure, and standardized data acquisition conditions 
across vendors, this study explores the need for systematic reproducibility for DW-MRI 
studies (95).
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5.3.2. Intra Voxel Incoherent Motion Diffusion Weighted MRI and Dynamic Con-
trast Enhanced MRI methods for tumor response assessment in Brain Me-
tastases - Experience at Memorial Sloan-Kettering Cancer Center, USA
BM are the most common intracranial tumors in adults. Furthermore, they repre-
sent an important cause of mortality (83). Measurements of annual BM incidence point 
towards an increase in incidence over the past several years, which has been attributed to 
several factors such as the improved ability of imaging modalities, an aging population, 
and better treatment of systemic disease. 
Both in the clinical and research settings it is essential to accurately assess wheth-
er or not a BM has been successfully treated and whether the metastasis requires addi-
tional treatment. The accurate assessment of treatment response by RT in BM is chal-
lenging because in some cases treated metastases can increase in size soon after therapy 
(156). Moreover, this increase in size happens in successfully treated metastases even in 
long term follow up assessment; in fact, Patel et al. found that one third of treated me-
tastases have transient increases in size (156). Radiation necrosis or pseudo-progression 
due to radiation can be challenging to differentiate from tumor recurrence by standard 
MRI (68). Obviously, in order to make the appropriate clinical decisions regarding fur-
ther therapy, which may include additional RT, it is essential to differentiate between 
these two eventualities. Clearly, a method that can accurately predict response soon after 
the completion of therapy would be advantageous over a method that requires long term 
clinical follow up. Hence, it is essential to develop noninvasive methods that will be able 
to determine if a metastasis has been successfully treated.
In terms of treatment options, SRS has emerged as one of the most important 
for the management of these tumors (157).  Because dose delivery is accurate to within 
one to two millimeters in SRS, the procedure is capable of delivering maximum dose 
within a target while minimizing the exposure of healthy surrounding tissue to ionizing 
radiation. To achieve this level of precision, SRS relies on 3-D imaging techniques such 
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as CT, MRI, and PET/CT to determine a tumor’s exact size, shape, and location within 
the patient, immobilization systems to ensure proper patient positioning and fixation 
throughout the therapy, highly focused gamma-ray or x-ray beams, and IGRT to confirm 
a tumor’s location before and sometimes during treatment. Despite these factors, which 
point to the relevance of BM and its treatment by SRS in radiation oncology, prospective 
studies in SRS treatment involving patients with BM are limited.
The scarcity of studies conducted in this area attest to a general dearth of infor-
mation and the need for further research. Jakubovic et al. studied, in 42 patients treated 
either WBRT or SRS, the potential of ADC as a treatment response biomarker, perform-
ing DW-MRI pre-, 1 week and 1 month post-treatment (158). They found that lower 
relative ADC values at 1 week and 1 month following radiation distinguished respond-
ers from non-responders. Earlier, Jakubovic et al. had also conducted a study of 70 
BM treated either with WBRT or SRS, to investigate the predictive ability of perfusion 
biomarkers from Dynamic susceptibility (DSC) to treatment response, performing DSC 
pre-, 1 week and 1 month post-treatment. They demonstrated that lower perfusion values 
can indentify responders and progressive disease patients (159). Huber et al. studied lo-
cal control and local failure by assessing contrast-enhancing volumes on T1w images in 
87 BM at 3 weeks and every 3 months post- SRS (70). The results suggested that volume 
on T1w images after SRS is a sensitive predictor of local failure.
The literature for the assessment of BM with MRI after SRS is sparse and even 
scarcer for advanced quantitative imaging (64, 70-73). Furthermore, there are no studies 
that assess response after SRS within 1-72 hours. 
This study calculated the diffusion related parameters as follows: ADC by using 
DW-MRI; and the true diffusion coefficient (D) and the perfusion factor (f) in BM by 
using IVIM DW-MRI, which was estimated by a bi-exponential fitting with multiple 
b-values. Meanwhile, DCE-MRI was analyzed by using the standard model approach. 
The perfusion biomarkers estimated provided information of the leakage rate of CA to 
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the extracellular space through Ktrans, vascularity information through vp and extracel-
lular space information through ve. The QIBs derived from DCE-MRI are complicated 
to estimate, and are still a challenge.  Their sensitivity can be influenced by different 
acquisition methods, processing techniques, and AIF estimation methods, all of which 
can affect reproducibility. When using standardized imaging protocols, changes in these 
DCE-MRI biomarkers are able to predict response or monitor the effects of RT treat-
ments.
This prospective study is the first of its kind to evaluate whether quantitative 
imaging metrics derived from IVIM DW- and DCE- MRI can assess early (1-72 hours 
post-Tx) treatment response in patients with BM treated with SRS. The results generated 
from this initial study are a building block for future studies with larger patient popula-
tions and have an application in adaptive RT in cancer.
The present study showed a significant strong positive correlation between mean 
ADC and mean D, mean f and mean vp and Ktrans, mean Ktrans and mean ve. ADC’s inverse 
correlation with cellularity is well-known, as tumors that grow at a high proliferation 
rate and have high cell density present lower ADC values (135). This characteristic of 
ADC, taken together with the increase in immature tumoral vessels that tends to be as-
sociated with the high proliferation of microvasculature, suggests a possible justification 
for these correlations (160, 161). 
The concept of assessing early response within 1-72 hours in BM patients treated 
with SRS is novel and showed substantial changes in the relative percent changes of 
the imaging metrics.  As much remains unexplained in the clinical realm in this setting, 
some studies attempt to understand tumor response to RT in preclinical settings. Garcia-
Barros et al. investigated the hypothesis that tumor response to radiation is determined 
not only by tumor cell phenotype but also by microvascular sensitivity in a preclinical 
study. MCA/129 fibrosarcomas and B16F1 melanomas grown in apoptosis-resistant acid 
sphingomyelinase (asmase)-deficient or Bax-deficient mice displayed markedly reduced 
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baseline microvascular endothelial apoptosis and grew 200 to 400% faster than tumors 
on wild-type microvasculature, indicating that endothelial apoptosis was a homeostatic 
factor regulating angiogenesis-dependent tumor growth. Moreover, these tumors exhib-
ited reduced endothelial apoptosis upon irradiation. This study showed that microvas-
cular damage regulates tumor cell response to radiation at the clinically relevant dose 
range (162). In a study that implanted human brain tumors in rats, Brown et al. showed 
that Ktrans decreases 24 hours post-SRS due to a reduce in blood flow supply (163). In ad-
dition, Song et al. showed that high-dose radiation causes prolonged ischemia that leads 
to additional cell killing (164). In a pre-clinical study conducted by Horsman et al. in 
mammary carcinoma, they showed a decrease in the Gd-uptake after 48 hours of a single 
dose radiation of 20 Gy (165). 
In the present study, ADC, D and Ktrans histograms display microstructural and 
microvasculature heterogeneity in tumor tissue and are consistent with previous reports 
(143). The early post-Tx ADC and Ktrans distribution curves illustrate the distribution of 
water molecules and contrast agent in the extracellular space compared to pre-Tx. A shift 
towards a higher ADC and lower Ktrans values reflect the improved pathologic response 
to SRS. The results in terms of response to treatment in a long term follow up of 12 
months show the same behavior of the tumor in terms of both the ADC values and tumor 
volumes for three representative patients.  
In this thesis it is shown that early changes in diffusion and perfusion imaging 
metrics to SRS can be detected in a manner similar to the changes seen by radiation ef-
fects in other studies. These exploratory results need in-depth study at both the preclini-
cal and clinical levels to decipher the actual biology that triggers the changes seen in the 
quantitative imaging metrics in RT setting.
Chapter VI
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Chapter VI: Conclusions and future work
 
This Ph.D. thesis is framed in the context of the modern advancement of RT towards 
individualized medicine. The use of imaging techniques such as CT, MRI and PET/CT have 
been established in the clinical flow to adapt RT treatment to the patient based on the anatomical 
information of the tumor provided by these techniques. The anatomical localization of the tumor 
plays a fundamental role in the application of RT treatment; this localization must be precise and 
reproducible for purposes of treatment planning and RT delivery. Among other methods that can 
ensure a high level of precision and reproducibility, the use of immobilization systems and flat 
tables has been routinely standardized. Functional information obtained from PET/CT is helping 
to complement this anatomical localization through even greater enhancements to precision, dem-
onstrating the relevance of the need for new tools in RT. The metabolism, diffusion and perfusion 
of the tumor measured through PET/CT and MRI, and the derived QIBs show different behaviors 
based on the specific type of tumor. In addition, these biomarkers show promise as predictors 
of prognosis and tumor response assessment, giving also microstructural and microvasculature 
information of tumors. This potential has been explored and examined in the studies below, with 
implications for the application and further study of functional imaging and QIBs in adaptive RT.
Part I of this thesis focuses on a population of HPV- HNSCC patients. The analysis of 
derived biomarkers (ADC and SUV) pre-, during and post-Tx, using the same immobilization 
devices in the acquisition of MRI and PET/CT data as in RT, showed that tumor cell density 
is inversely proportional to glucose metabolism of tumor. Furthermore, the survival status and 
functional biomarkers showed different trends for NED, AWD and DOD patients. A possibility 
to explore in the future is the optimization of the acquisition time to minimize the time in which 
the patient is fitted with a fixation mask. In addition, the specific disease type selected made 
recruitment highly selective; however, this selectivity is justified given that these subtypes of 
HPV- patients are the ones who have poor prognoses in HNSCC. 
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The results represent patterns in just three clinical outcome categories (NED, AWD and 
DOD) to show what features and what conditions are necessary to assess tumor response in this 
subtype of patients. In addition, this study offers insight into how to manage and understand 
valuable biomarkers, such as SUV and ADC, with the objective of integrating them into the 
development of adaptive RT in the future.
The need for the accurate localization of tumor for treatment planning and RT delivery 
was the focus of Part II of this thesis. Distortion in DW-MRI must therefore be minimized, 
an issue that this study attempted to resolve through the application of the reversed gradient 
method to DW-MRI to obtain a more accurate measurement of ADC. A clear improvement in 
mutual information for registration processes was observed when the reversed gradient method 
was applied. Thus, this method improves both registration and provides accurate ADC mea-
surement in tumors. The correction of distortion with the reversed gradient method should form 
part of an imaging method for treatment response using ADC metrics to assess tumor response 
or cell density variation with treatment in cancer patients.
Part III of the thesis focused on BM patients treated with SRS, analyzing diffusion and 
perfusion from DW-MRI and DCE-MRI pre- and early post-Tx to show early changes in dif-
fusion and perfusion imaging metrics due to SRS treatment. These changes can be detected in 
a manner similar to those associated with radiation effect in other studies. BM patient studies 
are still lacking, and the method proposed in this thesis is the first of its kind used to predict 
response at the early stages. This method is advantageous to others requiring long term clinical 
follow up, and will help to individualize and adapt RT treatment.
These results should be validated in larger populations and through multicenter studies 
in order to apply these biomarkers in the clinical setting of adaptive RT for HPV- HNSCC and 
BM. For this application to occur, ensuring reproducibility and repeatability is crucial. A par-
ticular procedure and standard data acquisition conditions for the systematic reproducibility of 
QIBs was tested in DW-MRI. A possibility to explore in the future is to further extend the spe-
cific procedure studied to DCE-MRI and IVIM DW-MRI. The new development of phantoms, 
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in collaboration with QIBA, presents an opportunity to do so. In addition, the development of 
new guidelines will provide a useful basis for the reproducibility and repeatability of selected 
QIBs.
 The three studies that constitute this thesis are an attempt to deepen our understanding 
of how to manage and use valuable information derived from the above mentioned functional 
imaging modalities in RT setting for cancer patients. After all, multimodality functional imag-
ing offers much more information about tumor biology and metabolism than the individual da-
tasets on their own and can be used as good predictors of treatment response with the possibility 
of implementing them in future adaptive RT.
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